programma ses - er congressi final program.pdf · 15 th international myeloma workshop w w w. i m w...

15TH INTERNATIONALMYELOMAWORKSHOP

WELCOME MESSAGE

Dear Colleagues and Friends,

It is my great pleasure and honor to invite you to attend the 15th International

Myeloma Workshop to be held in Rome, Italy, from September 23rd to 26th, 2015.

During this important biannual event, the emerging advances in the biology and

treatment of multiple myeloma, as well as debates on more controversial

arguments, and consensus report will be presented.

The location of the Workshop, in the Auditorium Parco della Musica which is right

in the city centre, will ensure that you all enjoy both the meeting and the fascinating

city of Rome.

I am very much looking forward to welcoming you to Rome in September 2015!

Antonio PalumboPresident, 15th International Myeloma Workshop

AUSPICES

Con l’adesione del Presidente della Repubblica ItalianaUnder the patronage of the President of the Italian Republic

Ministero della SaluteItalian Ministry of Health


ww

w.im

w20

15.c

om

Auditorium Parco della Musica

SEPTEMBER 23-26, 2015

TIMETABLE

Wednesday, September 23, 2015 Thursday, September 24, 2015 Friday, September 25, 2015 Saturday, September 26, 2015

07.00-08.0007.00-08.00MEET THE EXPERTS

07.00-08.00MEET THE EXPERTS

07.00-08.00MEET THE EXPERTS

08.00-09.00

09.00-10.00

08.00-10.20NEWLY DIAGNOSED MULTIPLE MYELOMAYOUNG PATIENTS

08.00-10.20NEWLY DIAGNOSED MULTIPLE MYELOMAELDERLY PATIENTS

08.00-09.00DEBATE

09.00-10.00RISING STARSAWARD

10.00-10.15BART BARLOGIE YOUNG INVESTIGATORAWARD

10.00-11.0009.45-11.00ROBERT KYLE LECTURES

10.20-10.50Coffee Break



10.50-12.20PRIME ONCOLOGY SPONSOREDSYMPOSIUM supported byTAKEDAONCOLOGYBuilding on the Foundation of ProteasomeInhibition in Multiple Myeloma

10.50-12.20CELGENE SPONSORED SYMPOSIUMThe Role of Immunomodulators in theFuture Landscape of Multiple Myeloma

10.30-11.00DEBATE

11.00-12.0011.00-13.00GENOMICSAND MICROENVIRONMENT

11.00-12.30PLENARYABSTRACT SESSION

12.00-13.0012.20-13.20Lunch

12.20-13.20Lunch

12.30-13.00CLOSING CEREMONY

13.00-14.0013.00-14.00Lunch 13.20-14.50

AMGEN SPONSORED SYMPOSIUMDelving Into the Deep – Advances in theTreatment of Multiple Myeloma in 2015

13.20-14.50JANSSEN SPONSORED SYMPOSIUMThe Clinical Rationale and Experience withMonoclonal Antibodies in Multiple Myeloma

13.00-14.00Lunch

14.00-15.00

14.00-16.00DIAGNOSTICAND RESPONSE CRITERIA

15.00-16.0014.50-16.30RELAPSED/REFRACTORY MULTIPLEMYELOMAPATIENTS

14.50-16.30IMMUNOTHERAPY

16.00-17.0016.00-16.30Coffee Break



17.00-18.00

16.30-18.00NOVARTIS SPONSORED SYMPOSIUMUnderstanding the Role of Epigenetics inthe Pathogenesis and Treatment of MultipleMyeloma

17.00-18.40ALLOGENEIC TRANSPLANTATIONANDNOVELAGENTS

17.00-18.40SPECIAL CONDITIONS

18.00-19.0018.00-18.45Waldenström's Award 18.40-19.40

POSTER SESSION I18.40-19.40POSTER SESSION II

19.00-20.00

18.45-19.15Patient Association Talks

19.15-19.30IMS General Assembly

20.00-21.0019.30-21.30Welcome Reception

2 3

09.30-09.45

OPENING CEREMONY


54



FACULTY

Kenneth C. Anderson Boston, USAMichel Attal Toulouse, FranceDaniel Auclair Norwalk, USAHervé Avet-Loiseau Toulouse, FranceDavid E. Avigan Boston, USANizar J. Bahlis Calgary, CanadaLuca Baldini Milano, ItalyBart Barlogie New York, USALeif P. Bergsagel Scottsdale, USAJoan Bladé Barcelona, SpainMario Boccadoro Torino, ItalyLawrence Boise Atlanta, USASara Bringhen Torino, ItalyJamie Cavenagh London, UKMichele Cavo Bologna, ItalyRaymond L. Comenzo Boston, USAAlessandro Corso Pavia, ItalyCarlo Croce Columbus, USAFaith Davies Little Rock, USAFrancesco Di Raimondo Catania, ItalyMeletios A. Dimopoulos Athens, GreeceAngela Dispenzieri Rochester, USABrian Durie Los Angeles, USAHermann Einsele Würzburg, GermanyMonika Engelhardt Freiburg, GermanyThierry Facon Lille, FranceJean-Paul Fermand Paris, FranceRafael Fonseca Scottsdale, USAFrancesca Gay Torino, ItalyMorie A. Gertz Rochester, USAIrene M. Ghobrial Boston, USASergio A. Giralt New York, USAHartmut Goldschmidt Heidelberg, GermanyRoman Hájek Ostrava, Czech RepublicJean-Luc Harousseau Saint Denis La Plaine, FranceJian Hou Shanghai, ChinaCynthia Iglesias York, United KingdomTadao Ishida Sapporo, JapanSudar Jagannath New York, USAAndrzej Jakubowiak Chicago, USANicolaus Kroeger Hamburg, GermanyShaji K. Kumar Rochester, USARobert Kyle Rochester, USAC. Ola Landgren New York, USA

Alessandra Larocca Torino, ItalyXavier Leleu Lille, FranceSagar Lonial Atlanta, USAHeinz Ludwig Vienna, AustriaAngelo Maiolino Rio de Janeiro, BrazilFabio Malavasi Torino, ItalyThomas G. Martin San Francisco, USAMaria-Victoria Mateos Salamanca, SpainPhilip L. McCarthy Buffalo, USAGiampalolo Merlini Pavia, ItalyFortunato Morabito Cosenza, ItalyPhilippe Moreau Nantes, FranceGareth J. Morgan Little Rock, USANikhil C. Munshi Boston, USAHirokazu Murakami Maebashi, JapanPellegrino Musto Rionero in Vulture (PZ), ItalyRuben Niesvizky New York, USASusie Novis Hollywood, USAMassimo Offidani Ancona, ItalyRobert Z. Orlowski Houston, USABruno Paiva Pamplona, SpainAntonio Palumbo Torino, ItalyFrancesca Patriarca Udine, ItalyMaria Teresa Petrucci Roma, ItalyTorben Plesner Vejle, DenmarkFelipe Prósper Pamplona, SpainNoopur Raje Boston, USAS. Vincent Rajkumar Rochester, USAPaul G. Richardson Boston , USAJesús F. San Miguel Pamplona, SpainJatin J. Shah Houston, USAKazuyuki Shimizu Kakamigahara, JapanPieter Sonneveld Rotterdam, The NetherlandsAndrew Spencer Melbourne, AustraliaEdward A. Stadtmauer Philadelphia, USAA. Keith Stewart Scottsdale, USAEvangelos Terpos Athens, GreecePatrizia Tosi Rimini, ItalySteven P. Treon Boston, USANiels van den Donk Amsterdam, The NetherlandsElena Zamagni Bologna, ItalyJeffrey A. Zonder Detroit, USASonja Zweegman Amsterdam, The Netherlands w

ww

.imw

2015

.co

m

HOTELAND SHUTTLE INFORMATION DESKThe congress will provide complimentary transfer service between the hotelsbooked through the IMW hotel booking office and the Auditorium Parco dellaMusica.Transfer services will run according to the meeting schedule. One ride in themorning and one in the evening. Please look for detailed shuttle bus schedules inyour hotel lobby and on the website (www.imw2015.it).

For further information about hotel accommodation and shuttle bus serviceprovided by the meeting please visit the Hotel and Shuttle Information Desk. Thedesk is located in the Registration Area and will be open during the following hours:

Wednesday, September 23, 2015 8:00 - 19:00

Thursday, September 24, 2015 8:00 - 19:00

Friday, September 25, 2015 8:00 - 19:00

Saturday, September 26, 2015 8:00 - 14:00

7

CONGRESS INFORMATIONVENUEAuditorium Parco della MusicaViale de Coubertin, 3000196 Rome (Italy)www.auditorium.com

HOWTO REACHThe Auditorium Parco della Musica of Rome is in Viale Pietro deCoubertin, near the Palazzetto dello Sport.The Auditorium Parco della Musica is in the Flaminio district of Rome,by the Villaggio Olimpico and can be easily reached by publictransport:

Bus Routes- 910, from Termini Station and Piazza Mancini- 53, from Piazza Mancini and Piazza San Silvestro- 217, from Viale XVII Olimpiade and Termini Station- 231, from Piazza Mancini and Piazzale Canestre (in Villa Borghesepark). Only weekends- Linea "M", special bus route between Termini station and VialePietro de Coubertin Auditorium stop. From 17h 00 - every 15 mins.Last bus from the Auditorium departs at the end of last event.

Tram routes- 2, from Piazzale Flaminio and Piazza Mancini

Trains- Metro A line to the Flaminio stop then no.2 tram- Or the Ferrovia Roma-Nord train to the Piazza Euclide stop

By car- From the G.R.A. (ring-road around Rome) take the Flaminio SaxaRubra exit towards Corso di Francia- From the Lungotevere Flaminio turn off into Viale Tiziano and thenagain at the Palazzetto dello Sport.

PARKINGAREAThere are large car parking facilities by the Auditorium Parco dellaMusica with designated areas for disabled visitors.

15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica


ww

w.im

w20

15.c

om

AUDITORIUM PARCO DELLA MUSICAPARKING and BUS STOP

6

9

ROME INFORMATION DESKFor all the information about the city (guided tours, museums, publictransportation, etc.), please visit the Rome Information Desk. The deskis located near the bar and will be open during the following hours:





REGISTRATION FEES

The registration fee includes:

- Participation in the scientific sessions- Access to the exhibition area- Conference kit- Attendance certificate- Lunches- Coffee breaks- Welcome reception- Abstracts e-book

REGISTRATION HOURS

INDIVIDUALS and EXHIBITORSTuesday, September 22, 2015 17:00 - 20.00





MEET THE EXPERTSTuesday, September 22, 2015 8:30 - 20:00




NURSETuesday, September 22, 2015 17:00 - 20:00


GROUPS & EXHIBITORSTuesday, September 22, 2015 8:30 - 16:30

BADGEBadges and meeting materials will be given at the counters in the registration area(ground floor of the Auditorium Parco della Musica). Remember to print and tobring with you in Rome the invitation letter and the badge barcode you received inthe “Registration Info” automatic e-mail.All registered participants, speakers, exhibitors and press staff, will be given abadge which must be worn in order to be admitted to the scientific sessions.Badge is mandatory to enter the congress area.

A self-printing system will be available in the Registration Area. Delegates, nursesand exhibitors will be able to collect their badges simply by having their personalbarcode scanned by the optical reader at the self-printing machines.Speakers and press staff are kindly requested to collect their badges at theRegistration desk.

The barcode on the badge stores the following personal information: name,surname, country and email address provided at the time of registration. It can beused by exhibitors to register visitors to their booths and to send additionalinformation on their products and services.



Registration Categories Onsite Registration

IMS Members € 650,00

Non-Member € 800,00

Nurses € 200,00

Exhibitors € 800,00

ww

w.im

w20

15.c

om

8

11

ATTENDANCE CERTIFICATEDelegates, nurses and speakers will be able to collect the attendancecertificates by having their personal barcode read at the self-printingmachines.The service will be available from September 23, 2015 evening.

CLOAKROOMAND LUGGAGEIn the cloakroom you can leave your belongings free of charge.The cloakroom is located in the Registration Area and will be open atthe following hours:

Wednesday, September 23, 2015 6.30 - 21:30

Thursday, September 24, 2015 6.30 - 20:00

Friday, September 25, 2015 6.30 - 20:00

Saturday, September 26, 2015 6.30 - 14:00

CATERINGLunches, coffee breaks and welcome cocktail are included in theregistration fee. No coupon is needed.Opening hours:

Wednesday, September 23, 2015 Lunch 13.00 - 14.00Coffee Break 16.00 - 16.30

Thursday, September 24, 2015 Coffee Break 10.20 - 10.50Lunch 12.20 - 13.20Coffee Break 16.30 - 17.00

Friday, September 25, 2015 Coffee Break 10.20 - 10.50Lunch 12.20 - 13.20Coffee Break 16.30 - 17.00

Saturday, September 26, 2015 Coffee Break 10.15 - 10.30Lunch 13.00 - 14.00

The IMW Welcome Cocktail is scheduled on September 23, 2015from 19.30 to 21.30 in the Cavea area. It is an outdoor standing buffetdinner.

The bar is located near the Exhibition Area and it will be open at the followinghours:

Tuesday, September 22, 2015 8.00 - 19:30

Wednesday, September 23, 2015 6.30 - 19:30

Thursday, September 24, 2015 6.30 - 19:30

Friday, September 25, 2015 6.30 - 19:30

Saturday, September 26, 2015 6.30 - 19:30

Direct payment in Euro.

PHOTOSANDAUDIO-VIDEO RECORDINGIndividual photos and audio-video recording are prohibited.Only authorized staff can provide photos and audio-video recording services.

INTERNETACCESSWiFi is available inside the Congress Area as follows:ID: IMW2015PASSWORD: TAKEDA2015An internet point will be available in the Exhibition area (see floor plan).

CASHWITHDRAWALA cash dispenser is located at the entrance of the meeting venue.Onsite payments should be made in Euro.

EXHIBITIONThe exhibition area will be open at the following hours:

Wednesday, September 23, 2015 9.00 – 21:00

Thursday, September 24, 2015 8.00 – 19:00

Friday, September 25, 2015 8.00 – 19:00

Saturday, September 26, 2015 8.00 – 14:00



ww

w.im

w20

15.c

om

10

13



ww

w.im

w20

15.c

om

12

EXHIBITIONAREAEXHIBITOR AREAAmgen B1Amgen Hospitality Suite B2Binding Site 13Bristol-Myers Squibb Co. GCelgene Corporation C1-D1Celgene Corporation Hospitality Suite C2-D2Doctors.MD Ltd. 8IMS - International Myeloma Society 10Janssen FKaryopharm Therapeutics Inc. 3Managing Myeloma 2Novartis Oncology 4-5-6-E1Novartis Oncology Hospitality Suite E2Takeda Oncology A1Takeda Oncology Hospitality Suite A216th International Myeloma Workshop 9

MEETING ROOMSSPONSOR ROOMAmgen Room B3Bristol-Myers Squibb Co. Room BBristol-Myers Squibb Co. Room ECelgene Corporation Room CCelgene Corporation Room DJanssen Room ATakeda Oncology Studio 1Takeda Oncology Studio 2Takeda Oncology Studio 3

1514



ww

w.im

w20

15.c

om

LANGUAGEThe Workshop will be in English with no simultaneous translation intoother languages.

ITALIAN CME CREDITSTwo Italian CME applications have been submitted as follows:

Main program (September 23-24-25-26, 2015):- Provider Studio ER Congressi SRL: ID 828-132558.- No. 11 CME credits for Physicians (Clinical Biochemistry, CardiacSurgery, Cardiology, General Surgery, Palliative Care, Haematology,Epidemiology, Pharmacology and Clinical Toxicology, MedicalGenetics, Geriatrics, Laboratory of Medical Genetics, GeneralMedicine, Internal Medicine, Nuclear Medicine, Microbiology andVirology, Oncology, Clinical Pathology, Radiotherapy), Biologists,Medical Laboratory Scientists, Nurses and Chemists.- Educational objective: “guidelines-protocols-procedures”.Poster sessions, meet the experts sessions, sponsored symposia arenot included in the submission.

In order to claim for credits attendees should:- wear a magnetic tag in order to register their presence inside thePlenary Hall. Please ask for it at the CME Registration Desk;

- attend at least the 80% of the submitted program;- complete the CME questionnaire. Please ask for it at the CMERegistration Desk on Saturday 26, 2015 morning;

- return the magnetic tag and the questionnaire at the end of themeeting.

Nursing Symposium (September 23, 2015):- Provider Studio ER Congressi SRL: ID 828-132580.- No. 5 CME credits for Nurses.- Educational objective: “guidelines-protocols-procedures”.

In order to claim for credits nurses should:- sign the attendance list at the entrance of the Teatro Studio Hall;- attend the 100% of the Nursing Symposium;- complete the CME questionnaire. Please ask for it at the entrance ofthe Teatro Studio Hall on Wednesday 23, 2015 afternoon;

- return the questionnaire at the end of the Nursing Symposium

CME certificates will be sent after the meeting by email.

SCIENTIFIC INFORMATIONEBAH CME CREDITSThe program of the “15th International Myeloma Workshop” has been reviewedand approved for CME accreditation by the European Board for Accreditation inHematology (EBAH), an independent accreditation body endorsed by EHA. TheEBAH Unit has approved this educational activity for no. 25 CME credits forPhysicians, Biologists, Medical Laboratory Scientists, Nurses and Chemists. EBAHCredit Points will be awarded for the Plenary Sessions and Meet the ExpertsSessions.To request credits, please fill out the form and return it to the registration desk atthe end of the meeting.We remind you that it is necessary to have an EBAH-CME account in order toclaim for credits. Attendees can create an EBAH-CME account registering on thewebsite: http://ebach.org even on site.

TEXTMESSAGEAND VOTING FLAGSText message system is available during the whole meeting in order to improvediscussion during the plenary sessions.Voting green/red flags for the Debate sessions are available inside the Plenary Hallin order to improve the interaction between attendees and speakers.

POSTERAREAPoster sessions will take place in the Poster Area.Opening hours:

Installation Wednesday, September 23, 2015 14.00 - 19.00Viewing Thursday, September 24, 2015 8.00 - 20.00

Friday, September 25, 2015 8.00 - 20.00Saturday, September 26, 2015 8.00 - 13.00

Best Poster Discussion Thursday, September 24, 2015 18.40 - 19.40Friday, September 25, 2015 18.40 - 19.40

Tear off Saturday, September 26, 2015 13.00 - 14.00

Posters should be installed/removed during the indicated set-up time (see above).Materials to hang posters with will be available at the poster area. The Congressprovides one board for each poster, the author is responsible for hanging and forremoving the poster. Please note that the organisers do not take any responsibilityfor returning uncollected material to the authors. There will be a poster helpdesk inthe poster area where staff will be happy to assist you.Posters will be on display in the Poster Area for three days and will be open forviewing on Thursday, Friday and Saturday.The best posters will be presented during Poster walking session on Thursday andFriday from 18.40 to 19.40.

17



SLIDE CENTER/SPEAKERS’AREAOpening hours:Wednesday, September 23, 2015 7.30 - 19.00

Thursday, September 24, 2015 6.30 - 19.00

Friday, September 25, 2015 6.30 - 19.00

Saturday, September 26, 2015 6.30 - 14.00

MEET THE EXPERTS SESSIONSThere will be four Meet the Experts Sessions on September 24,September 25 and September 26 from 7.00 to 8.00. The registrationis not included in the Registration Fee.It costs Euro 25,00 per day (VAT included). Each session is restrictedto 25 participants.Preregistration for these sessions is necessary. Tickets can also bepurchased during registration hours at the Registration Desk if stillavailable.All Meet the Expert Sessions are located in TEATRO STUDIO HALL asfollows:

ww

w.im

w20

15.c

om

16

Thursday, Sep 24, 2015 Friday, Sep 25, 2015 Saturday, Sep 26, 2015

Diagnostic CriteriaXavier Leleu, Elena ZamagniGREEN ROOM

Monoclonal Gammopathyof UndeterminedSignificance - SmolderingMultiple MyelomaLuca Baldini,Brian G.M. DurieGREEN ROOM

Amyloid Light-chainAmyloidosisRaymond L. Comenzo,Fortunato MorabitoGREEN ROOM

Newly Diagnosed MultipleMyeloma Patients < 65 years,High-risk Patients: How to treatMichele Cavo,Francesca PatriarcaRED ROOM

Newly Diagnosed MultipleMyeloma Fit Patients > 65years: How to treatRuben Niesvizky,Massimo OffidaniRED ROOM

WaldenströmMacroglobulinemiaPellegrino Musto,Steven P. TreonRED ROOM

Newly Diagnosed MultipleMyeloma Patients < 65 years,Low-risk Patients: How to treatMario Boccadoro,Andrzej J. JakubowiakBLUE ROOM

Newly Diagnosed MultipleMyeloma Frail Patients >65 years: How to treatSara Bringhen,Sonja ZweegmanBLUE ROOM

Bone DiseaseNoopur Raje,Patrizia TosiBLUE ROOM

Relapsed/Refractory MultipleMyeloma 1-3 Previous Linesof Therapy: How to treatFaith E. Davies,Francesco Di RaimondoYELLOW ROOM

Relapsed/RefractoryMultiple Myeloma 4-6Previous Lines of Therapy:How to treatAlessandro Corso,Sundar JagannathYELLOW ROOM

Supportive CareJoan Bladé,Maria Teresa PetrucciYELLOW ROOM

AWARDSWALDNESTRÖM’S AWARDRecognition for a lifetime achievement for contributions to multiple myelomaresearch. The award is named for Professor Jan Waldenström, who was a pioneerin treating blood cancers. The award presentation is scheduled on September 23,2015 at 18.00 in the Plenary Session.

RISING STARS AWARDThe Scientific Committee selected the best four abstracts submitted by authorsunder 35 years of age.These abstracts will be presented in plenary session on Saturday from 9.00 to10.00. The authors will receive a check of Euro 5.000,00 onsite.

BART BARLOGIE YOUNG INVESTIGATOR AWARDIn recognition to the outstanding research developed by Dr. Bart Barlogie in the fieldof multiple myeloma, the IMS Board of Directors decided to establish the BartBarlogie Young Investigator Award. This award is aimed at formally recognizingand stimulating excellence in myeloma research. The Young Investigator Awardwill be given to an investigator under the age of 40 years in recognition of theirresearch in the myeloma field. An Award of US $25,000 by the IMS will be givenat each of the International Myeloma Workshops, beginning with Rome inSeptember 2015.The award presentation is scheduled on September 26, 2015 at 10.00 in thePlenary Session.

IMWAPPA special mobile app has been developed for this congress in which you can findthe entire program and further information. Use the app to find sessions of interest,create your own program, find and read all the abstracts.Download the “IMW2015” app from the Apple App store or Google-Play.

OFFICIALWEBSITEwww.imw2015.it

CHANGESParts of the program may be changed without prior notice.

19




SEPTEMBER 23 - 26, 2015Rome,Auditorium Parco della Musica

PROGRAM

www.imw2015.com

18

OPENING HOURS

Tuesday,September 22,

2015

Wednesday,September 23,

2015

Thursday,September 24,

2015

Friday,September 25,

2015

Saturday,September 26,

2015

RegistrationArea 8.30 - 20.00 6.30 - 20.00 6.30 - 20.00 6.30 - 20.00 6.30 - 14.00

Slide Center/Speakers’Area 7.30 - 19.00 6.30 - 19.00 6.30 - 19.00 6.30 - 14.00

Cloakroom 6.30 - 21.30 6.30 - 20.00 6.30 - 20.00 6.30 - 14.00

ExhibitionArea 9.00 - 21.00 8.00 - 19.00 8.00 - 19.00 8.00 - 14.00

Poster Area 8.00 - 20.00 8.00 - 20.00 8.00 - 13.00

Rome Information Desk 8.00 - 19.00 8.00 - 19.00 8.00 - 19.00 8.00 - 14.00

Hotel and Shuttle Info Desk 8.00 - 19.00 8.00 - 19.00 8.00 - 19.00 8.00 - 14.00

Bar 8.00 - 19.30 6.30 - 19.30 6.30 - 19.30 6.30 - 19.30 6.30 - 19.30

SERVICES PROVIDED

Service Name Location

Abstract e-book Congress Kit Registration Area

Cash Withdrawal Cash Dispenser Meeting Venue Entrance

City Information Rome Information Desk Exhibition Area

Cloakroom and Luggage Cloakroom Registration Area

Internet Internet Point Exhibition Area

WiFi Wireless Internet Throughout the Venue

Exhibition Information Exhibitor Help Desk Exhibition Area

Hotel and Shuttle Information Hotel and Shuttle Information Desk Registration Area

Meet the Experts Tickets Registration Desk Registration Area

Vatican Museum Tickets Registration Desk Registration Area

Poster Information Poster Help Desk Poster Area

20 21

Wednesday, September 23, 2015

09.30-09.45 OPENING CEREMONY SANTA CECILIA HALL

ROBERT KYLE LECTURESChairmen: Robert Kyle, Antonio Palumbo

09.45-10.30 Access to Innovation and Quality of Care in the Context ofEconomic Constraints: a Challenge for HealthcareJean-Luc Harousseau

10.30-11.00 How to introduce TechnologyAssessment in Clinical StudiesCynthia Iglesias

GENOMICSAND MICROENVIRONMENT SANTA CECILIA HALL

Chairmen: Gareth J. Morgan, Nikhil C. Munshi

11.00-11.20 Next Generation SequencingNikhil C. Munshi

11.20-11.40 Gene Expression ProfilePieter Sonneveld

11.40-12.00 SNP/microRNACarlo Croce

12.00-12.20 The Vk*MYC Mouse Model to study Drug and ImmunotherapyResponse and ResistanceP. Leif Bergsagel

12.20-12.40 Multiple Myeloma Biological PathwaysGareth J. Morgan

12.40-13.00 Multiple Myeloma and Bone Marrow NicheIrene M. Ghobrial

13.00-14.00 Lunch EXHIBITION AREA

CMECME CMECME

CMECME CMECME



DIAGNOSTICAND RESPONSE CRITERIA SANTA CECILIA HALL

Chairmen: Hervé Avet-Loiseau, S. Vincent Rajkumar

14.00-14.20 New Diagnostic Criteria for Multiple MyelomaS. Vincent Rajkumar

14.20-14.40 Flow Cytometry for Minimal Residual DiseaseBruno Paiva

14.40-15.00 Next Generation Sequencing for Minimal Residual DiseaseHervé Avet-Loiseau

15.00-15.20 Imaging TechniquesElena Zamagni

15.20-15.40 RiskAssessment and StratificationRafael Fonseca

15.40-16.00 Geriatric Assessment and StratificationAlessandra Larocca

16.00-16.30 Coffee break EXHIBITION AREA

NOVARTIS SPONSORED SYMPOSIUM SANTA CECILIA HALL

Understanding the Role of Epigenetics in the Pathogenesisand Treatment of Multiple MyelomaChairman: Jesús F. San Miguel

16.30-16.40 Welcome and Opening RemarksJesús F. San Miguel

16.40-16.55 Introduction to Epigenetics and its Role in the Pathogenesis ofHematologic MalignanciesFelipe Prósper

16.55-17.15 Rationale for Targeting Epigenetic Mechanisms in MultipleMyelomaAndrew Spencer

CMECME CMECME


2322


17.15-17.35 Clinical Update on Pan-Deacetylase Inhibitors in Multiple MyelomaJamie D. Cavenagh

17.35-17.55 Opportunities for Novel Combinations withAgents TargetingEpigenetic MechanismsHermann Einsele

17.55-18.00 Closing RemarksJesús F. San Miguel

Chairmen: Kenneth C. Anderson, Robert Kyle SANTA CECILIA HALL

18.00-18.45 Waldenström's Award

18.45-19.15 Patient Association Talks

• International Myeloma FoundationSusie Novis

• Multiple Myeloma Research FoundationDaniel Auclair

19.15-19.30 IMS General Assembly

19.30-21.30 Welcome Reception CAVEA AREA


CMECME CMECME

Qursday, September 24, 2015

MEET THE EXPERTS TEATRO STUDIO HALL

Simultaneous sessions in four rooms

07.00-08.00 Diagnostic Criteria GREEN ROOM

Xavier Leleu, Elena Zamagni

07.00-08.00 Newly Diagnosed Multiple Myeloma Patients < 65 years, RED ROOM

High-risk Patients: How to treatMichele Cavo, Francesca Patriarca

07.00-08.00 Newly Diagnosed Multiple Myeloma Patients < 65 years, BLUE ROOM

Low-risk Patients: How to treatMario Boccadoro, Andrzej J. Jakubowiak

07.00-08.00 Relapsed/Refractory Multiple Myeloma 1-3 Previous YELLOW ROOM

Lines of Therapy: How to treatFaith E. Davies, Francesco Di Raimondo

NEWLY DIAGNOSED MULTIPLE MYELOMA SANTA CECILIA HALL

YOUNG PATIENTSChairmen: Michele Cavo, Angelo Maiolino

08.00-08.20 Optimal InductionMichel Attal

08.20-08.40 Single-tandem TransplantationHermann Einsele

08.40-09.00 Optimal Consolidation TherapyMichele Cavo

09.00-09.20 Transplant Eligible MaintenancePhilip L. McCarthy

09.20-09.40 Ongoing Studies/Open Questions inAmericaSergio A. Giralt

09.40-10.00 Ongoing Studies/Open Questions in EuropeRoman Hájek

10.00-10.20 Ongoing Studies/Open Questions inAsia PacificJian Hou


CMECME

CMECME CMECME


25


PRIME ONCOLOGY SPONSORED SYMPOSIUM SANTA CECILIA HALL

Supported by TAKEDAONCOLOGYBuilding on the Foundation of Proteasome Inhibition inMultiple MyelomaChairman: Mario Boccadoro

10.50-10.52 Welcome and IntroductionMario Boccadoro

10.52-10.55 “Myeloma Guru”Questions

10.55-11.10 Targeting the Ubiquitin-proteasome System in Multiple Myeloma:Examining the Roots of SuccessPaul G. Richardson


11.15-11.30 Challenges and Solutions with First-generation ProteasomeInhibition: Practical StrategiesMaría-Victoria Mateos


11.35-11.50 Second-generation Proteasome Inhibition: What a Difference aGeneration makesMario Boccadoro


11.55-12.10 Implications of Oral Proteasome Inhibition: Impact on PatientsShaji K. Kumar

12.10-12.20 Audience Questions and Faculty Panel Discussion

12.20 Adjourn



AMGEN SPONSORED SYMPOSIUM SANTA CECILIA HALL

Delving Into the Deep –Advances in the Treatmentof Multiple Myeloma in 2015Chairman: Antonio Palumbo

13.20-13.25 Welcome and IntroductionAntonio Palumbo

13.25-13.42 Reaching Beyond Overall Response in Patients with MultipleMyelomaPhilippe Moreau

13.42-13.59 Two-drug Combinations in the Treatment of Multiple MyelomaMeletios A. Dimopoulos

13.59-14.16 Three-drug Combinations in the Treatment of Multiple MyelomaA. Keith Stewart

14.16-14.33 The Evolving Role of Proteasome Inhibition in Multiple MyelomaAntonio Palumbo

14.33-14.48 Panel Discussion

14.48-14.50 Summary and CloseAntonio Palumbo

RELAPSED/REFRACTORY MULTIPLE SANTA CECILIA HALL

MYELOMAPATIENTSChairmen: Joan Bladé, Sundar Jagannath

14.50-15.10 How I treat Relapsed/Refractory Multiple Myeloma, SequenceStrategy, Patient SelectionRobert Orlowski

15.10-15.30 How I treat Refractory Disease and Extramedullary DiseaseJoan Bladé

15.30-15.50 How I treat Serious Adverse EventsHeinz Ludwig

15.50-16.10 How I use Bone SupportEvangelos Terpos

16.10-16.30 How I use Supportive Care and PalliationFrancesca Gay


CMECME CMECME

24


2726


ALLOGENEIC TRANSPLANTATIONAND SANTA CECILIA HALL

NOVELAGENTSChairmen: Nicolaus Kroeger, Andrew Spencer

17.00-17.20 Significance of Allogenic Stem Cell TransplantationNicolaus Kroeger

17.20-17.40 Selective Histone Deacetylase InhibitorNoopur Raje

17.40-18.00 Inhibitors (KPT – KSP)Jatin J. Shah

18.00-18.20 Inhibitors (BCL2 - MCL1 - CDK)Lawrence Boise

18.20-18.40 Targeting Oncogenic Pathways in Myeloma (MEK- PI3K -AKT)Andrew Spencer

POSTER SESSION I POSTER AREA

18.40-19.40 Multiple Myeloma Genomics, Diagnosis, Prognosis, ImagingChairman: Nizar J. Bahlis

18.40-19.40 Multiple Myeloma Therapy in Newly Diagnosed Patients includingTransplantationChairman: Andrzej J. Jakubowiak

18.40-19.40 Epidemiology, QoL, Toxicities, and Other Plasma Cell DyscrasiasChairman: Raymond L. Comenzo


CMECME CMECME Friday, September 25, 2015



07.00-08.00 Monoclonal Gammopathy of Undetermined GREEN ROOM

Significance - Smoldering Multiple MyelomaLuca Baldini, Brian G.M. Durie

07.00-08.00 Newly Diagnosed Multiple Myeloma Fit Patients > 65 years: RED ROOM

How to treatRuben Niesvizky, Massimo Offidani

07.00-08.00 NewlyDiagnosedMultipleMyelomaFrail Patients > 65 years: BLUE ROOM

How to treatSara Bringhen, Sonja Zweegman

07.00-08.00 Relapsed/Refractory Multiple Myeloma 4-6 Previous YELLOW ROOM

Lines of Therapy: How to treatAlessandro Corso, Sundar Jagannath

NEWLY DIAGNOSED MULTIPLE MYELOMA SANTA CECILIA HALL

ELDERLY PATIENTSChairmen: Hirokazu Murakami, Paul G. Richardson

08.00-08.20 Debate - Change Therapy for High/Low Risk Patients - YesS. Vincent Rajkumar

08.20-08.40 Debate - Change Therapy for High/Low Risk Patients - NoPaul G. Richardson

08.40-09.00 Optimal Therapy for Fit Elderly PatientsRuben Niesvizky

09.00-09.20 Optimal Therapy for Unfit Elderly PatientsSonja Zweegman

09.20-09.40 Ongoing Studies/Open Questions inAmericaMorie A. Gertz

CMECME CMECME

CMECME


29


09.40-10.00 Ongoing Studies/Open Questions in EuropeMonika Engelhardt

10.00-10.20 Ongoing Studies/Open Questions inAsia PacificTadao Ishida


CELGENE SPONSORED SYMPOSIUM SANTA CECILIA HALL

The Role of Immunomodulators in the Future Landscapeof Multiple MyelomaChairman: Michele Cavo

10.50-10.55 WelcomeMichele Cavo

10.55-11.10 Multiple Myeloma – Coping with a Disrupted Immune EnvironmentKenneth C. Anderson

11.10-11.25 Continuous Therapy for Elderly Newly Diagnosed Multiple MyelomaThierry Facon

11.25-11.40 IMiD-based Triplet Therapy for Multiple MyelomaSagar Lonial

11.40-11.55 Clonal Evolution – Disease ChallengesGareth J. Morgan

11.55-12.10 Beyond Lenalidomide: PomalidomideMeletios A. Dimopoulos

12.10-12.20 Questions and Discussion



28

JANSSEN SPONSORED SYMPOSIUM SANTA CECILIA HALL

The Clinical Rationale and Experience with MonoclonalAntibodies in Multiple MyelomaChairmen: Antonio Palumbo, Jesús F. San Miguel

What is the Role for Monoclonal Antibodies in Multiple Myeloma?13.20-13.30 Understanding the Biological Rationale

Fabio Malavasi

13.30-13.40 What do the Preclinical Data tell us?Sagar Lonial


Current Clinical Experience with anti-CD38 Monoclonal Antibodies:13.50-14.00 Single Agent Activity

Jesús F. San Miguel

14.00-14.10 Combination StudiesAntonio Palumbo

14.10-14.30 Practical Management Consideration for Patients Receivinganti-CD38 Monoclonal AntibodiesPhilippe Moreau


IMMUNOTHERAPY SANTA CECILIA HALL

Chairmen: David E. Avigan, Thierry Facon

14.50-15.10 SLAMF7 Combinational Monoclonal Antibodies TherapyThierry Facon

15.10-15.30 CD38, Novel Monoclonal Antibodies Targets, ImmunotoxinThomas G. Martin

15.30-15.50 PD1 - PDL1 - VaccineDavid E. Avigan

15.50-16.10 CAR-TEdward A. Stadtmauer

16.10-16.30 Bispecific Monoclonal AntibodiesJeffrey A. Zonder


CMECME CMECME


31


SPECIAL CONDITIONS SANTA CECILIA HALL

Chairmen: Angela Dispenzieri, Jean-Paul Fermand

17.00-17.20 Monoclonal Gammopathy of Undetermined SignificanceAngela Dispenzieri

17.20-17.40 Smoldering Multiple MyelomaMaría-Victoria Mateos

17.40-18.00 Primary Plasma Cell LeukemiaNiels van de Donk

18.00-18.20 Amyloid Light-chainAmyloidosisGiampaolo Merlini

18.20-18.40 Waldenström MacroglobulinemiaSteven P. Treon

POSTER SESSION II POSTER AREA

18.40-19.40 Multiple Myeloma Biology, Pathophysiology, Preclinical Studies,Bone DiseaseChairman: Noopur Raje

18.40-19.40 Multiple Myeloma Therapy in Newly Diagnosed Patients excludingTransplantationChairman: Heinz Ludwig

18.40-19.40 Multiple Myeloma Therapy Relapsed/Refractory PatientsChairman: Torben Plesner


CMECME CMECME Saturday, September 26, 2015



07.00-08.00 Amyloid Light-chainAmyloidosis GREEN ROOM

Raymond L. Comenzo, Fortunato Morabito

07.00-08.00 Waldenström Macroglobulinemia RED ROOM

Pellegrino Musto, Steven P. Treon

07.00-08.00 Bone Disease BLUE ROOM

Noopur Raje, Patrizia Tosi

07.00-08.00 Supportive Care YELLOW ROOM

Joan Bladé, Maria Teresa Petrucci

DEBATE SANTA CECILIA HALL

Chairmen: Brian G.M. Durie, Antonio Palumbo

08.00-08.15 Biomarker to change Therapy Minimal Residual Disease/Imagingvs FISH/Age - in Favor of Minimal Residual Disease/ImagingC. Ola Landgren

08.15-08.30 Biomarker to change Therapy Minimal Residual Disease/Imagingvs FISH/Age - in Favor of FISH/AgePieter Sonneveld

08.30-08.45 Can we cure Multiple Myeloma by 2020? YesBart Barlogie

08.45-09.00 Can we cure Multiple Myeloma by 2020? NoHartmut Goldschmidt

RISING STARSAWARD SANTA CECILIA HALL

Chairmen: Brian G.M. Durie, Antonio Palumbo

09.00-09.15 RS-001

Hedgehog Pathway over Expression Identifies Myeloma Patientswith worse PrognosisMarina Martello

CMECME

CMECME CMECME

CMECME CMECME

30


3332


09.15-09.30 RS-002

Preclinical Analysis of Feasibility and Efficacy of CS1 DirectedCAR T cell Therapy in Multiple Myeloma in theAutologous SettingSophia Danhof

09.30-09.45 RS-003

Carfilzomib and Dexamethasone in Untreated SymptomaticMultiple MyelomaPeter Forsberg

09.45-10.00 RS-004

Ribosomal dysfunction inAL amyloidosis: Gene ExpressionProfile Meta-AnalysisFedor Kryukov

BARTBARLOGIE YOUNG INVESTIGATIONAWARD10.00-10.15 Chairmen: Kenneth C. Anderson, Bart Barlogie, Joan Bladé


DEBATE SANTA CECILIA HALL

Chairmen: Mario Boccadoro, Hermann Einsele

10.30-10.45 How to incorporate the Newest Agents Combo vs Sequence -in Favor of ComboFaith E. Davies

10.45-11.00 How to incorporate the Newest Agents Combo vs Sequence -in Favor of SequenceShaji K. Kumar

PLENARYABSTRACT SESSION SANTA CECILIA HALL

Chairmen: Mario Boccadoro, Hermann Einsele

11.00-11.15 OP-001

AMeta-Analysis Investigating the Impact of Minimal ResidualDisease (MRD) Status on Survival Outcomes in Patients withMultiple Myeloma (MM) whoAchieve Complete Response (CR)Nikhil Munshi


CMECME CMECME

CMECME CMECME

11.15-11.30 OP-002

Genome-scale CRISPR-Cas9 Knockout Studies to characterize theMechanisms of Myeloma Cell Treatment ResistanceYiguo Hu

11.30-11.45 OP-003

Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX)(KRd) combined withAutologous Stem Sell Transplant (ASCT) showsEmproved Efficacy compared with KRd without ASCT in NewlyDiagnosed Multiple Myeloma (NDMM)Andrzej J. Jakubowiak

11.45-12.00 OP-004

Early Mortality in Elderly Patients with Newly Diagnosed MultipleMyeloma Treated with Novel AgentsAlessandra Larocca

12.00-12.15 OP-005

Phase 1, Multicenter, Open-label, Dose-escalation, CombinationStudy (NCT02103335) of Pomalidomide (POM), Marizomib(MRZ, NPI-0052), and Dexamethasone (DEX) in Patients withRelapsed and Refractory Multiple Myeloma (MM);Study NPI-0052-107 Preliminary ResultsAndrew Spencer

12.15-12.30 OP-006

The Genomic and Transcriptional Landscape of Waldenström’sMacroglobulinemia Impacts Disease Presentation, Overall Survivaland Therapeutic ResponseZachary Hunter

12.30-13.00 CLOSING CEREMONY SANTA CECILIA HALL


34 35

Wednesday, September 23, 2015

10.45-11.00 Welcome and OpenElena Ponticelli, Tracy King

MANAGING TOXICITIESAND SYMPTOMS TEATRO STUDIO HALL

Chairmen: Daniela Klarica, Tiffany Richards

11.00-11.40 Keeping Patients on Treatment: Management of ToxicitiesRelated to New Therapies and Challenges of SymptomManagement ResearchBeth Faiman

11.40-12.00 Toxicities Associated with SQ Bortezomib: an Update ofthe Italian ExperienceAlessandra Malfitano

12.00-12.20 Evidenced Based Practice for Central Line Care: Impact ofNew Therapies on Utilization of VenousAccess Devices byPatients with MyelomaAnnalisa Bernardini

12.20-12.40 The Devils in the Dex: the Experience of High DoseDexamethasone and Implications for PRO Tool DevelopmentTracy King

12.40-13.00 “We are the Nurses all the Time”: the Experience and SupportiveCare Needs of the Family in the Era of Novel Myeloma TherapiesMonica Morris

13.00-14.00 Lunch



Annalisa Bernardini Torino, ItalyBeth Faiman Cleveland, USATracy King Sidney, AustraliaDaniela Klarica Melbourne, AustraliaAlessandra Malfitano Torino, ItalyMonica Morris Edinburgh, United KingdomElena Ponticelli Torino, ItalyTiffany Richards Houston, USAJoseph Tariman Chicago, USA

PROGRAM

FACULTY

2nd MYELOMANURSING SYMPOSIUM

36 37



ABSTRACT SESSION TEATRO STUDIO HALL

Chairman: Beth Faiman

14.00-14.20 NO-001

Lack of Health Maintenance Exams and Risk: an Internet-BasedSurvey on Health Maintenance and Preventive Care Patterns inPatients with MyelomaJoseph D. Tariman

14.20-14.40 NO-002

ACAM doApproach: the attitudes, Use and Disclosure of the Use ofComplementary andAlternative Medicine (CAM) in those with myelomaTracy King

14.40-15.00 NO-003

APilot Placebo Controlled Study to Estimate the Effect Size ofGlutamine to Prevent Peripheral Neuropathy in Multiple MyelomaBeth Faiman

15.00-15.20 NO-004

Development of a Nurse Led Community based Bortezomib Programfor Multiple Myeloma (MM)Daniela Klarica

15.20-15.40 NO-005

Aplasia on the own Couch at Home in Multiple Myeloma Patientsafter Autologous Stem Cell TransplantationIris Agreiter

15.40-16.00 NO-006

Cellular Immunotherapy for Myeloma using Chimeric AntigenReceptor Modified T Cells (CARs)Patricia Mangan

16.00-16.30 Coffee break

NURSING PLENARY TEATRO STUDIO HALL

Chairman: Monica Morris

16.30-17.15 Integrating Myeloma Genomics into Nursing Practice: PatientEducation and Shared Decision MakingJoseph D. Tariman

17.15-17.35 Formation of International Nurses SocietyTracy King

17.35-17.45 IMW 2017 New Delhi Summary and CloseElena Ponticelli, Tracy King

GENERAL INFORMATION OF THE NURSING SYMPOSIUM

VENUETeatro Studio HallAuditorium Parco della MusicaViale de Coubertin, 3000196 Rome (Italy)www.auditorium.com

POSTERPoster session will take place in the Teatro Studio Hall:

InstallationWednesday, September 23, 2015 9.30 - 10.30 Teatro Studio Hall

ViewingWednesday, September 23, 2015 10.30 - 18.00 Teatro Studio HallThursday, September 24, 2015 8.00 - 20.00 Poster AreaFriday, September 25, 2015 8.00 - 20.00 Poster AreaSaturday, September 26, 2015 8.00 - 13.00 Poster Area

Tear offSaturday, September 26, 2015 13.00 -14.00 Poster Area

Posters should be installed in Teatro Studio Hall, on the back of the room in orderto make posters available during the Nursing Symposium. At the end of thesymposium, the Organizing Secretariat staff will move posters in the Poster Area ofthe meeting.Materials to hang posters with will be available in Teatro Studio Hall. The Congressprovides one board for each poster. The author is responsible for hanging and forremoving the poster. Please note that the organisers do not take any responsibilityfor returning uncollected material to the authors. There will be a poster helpdeskwhere staff will be happy to assist you.

38 39

INTERIM ANALYSIS OF THE MMRF COMMPASS STUDY: COM-PREHENSIVE CHARACTERIZATION OF MULTIPLE MYELOMAPATIENTS AT DIAGNOSIS REVEALS DISTINCT MOLECULARSUBTYPESAND CLINICAL OUTCOMES

MOLECULAR RISK STRATIFICATION OF 1,036 CASES FROM THENCRIMYELOMAXI TRIALUSINGTHEALL-MOLECULARDIAGNOSTICTOOLMYMAP (MYELOMAMLPAAND TRANSLOCATION PCR)

NONINVASIVE DIAGNOSIS OF ACTIONABLE MUTATIONS BY DEEPSEQUENCING OF CIRCULATING CELL FREE DNA (CFDNA) INMULTIPLE MYELOMA (MM)

RARE HIGH RISK IGH TRANSLOCATIONS IN NEWLY DIAGNOSEDMULTIPLE MYELOMA (MM): CYTOGENETIC CHARACTERIZATIONAND RELEVANCE ON PROGNOSIS

JUMPING TRANSLOCATIONS OF 1Q12 IN MULTIPLE MYELOMA:UNEXPECTED INTRA-CLONALHETEROGENEITYOFCOPYNUMBERABERRATIONS IN THE 1Q21-31 REGION

CIRCULATINGEXOSOMALMICRORNASARECRITICALPROGNOSTICMARKERS INDEPENDENTOFCYTOGENETICSAND INTERNATIONALSTAGING SYSTEM IN MULTIPLE MYELOMA

GENE EXPRESSION PROFILE OF MULTIPLE MYELOMA PATIENTSWITH POOR RESPONSE TO BORTEZOMIB INDUCTION THERAPY INTHE HOVON65/GMMG-HD4 STUDY

THE IMPACT OF NORMAL PLASMA CELL RECOVERY ON PRO-GRESSION-FREE AND OVERALL SURVIVAL IN MYELOMA PATIENTSAFTERASCT

MULTIPLE MYELOMA SUBTYPING THAT ASSOCIATES NORMAL B-CELL SUBSET PHENOTYPES, DO CORRELATE TO DISEASE STAGEAND PROGNOSIS - INDICATION OF REVERSIBLE PHENOTYPICPLASTICITYASAHALLMARK

POSTER

1. Multiple Myeloma Genomics, Diagnosis, Prognosis, Imaging

POSTER DISCUSSION SESSIONChairman: Nizar J. Bahlis

J. Keats

M.F. Kaiser

R. Kaedbey

G. Marzocchi

J. Sawyer

S. Manier

M. Van Duin

A.C. Rawstron

H.E. Johnsen

BP-001

BP-002

BP-003

BP-004

BP-005

BP-006

BP-008

BP-009

BP-010




4140 4140



USEFULNESS OF WHOLE-BODY DIFFUSION-WEIGHTED MRI (WB-MRI) WITH APPARENT DIFFUSION COEFFICIENT (ADC) IN THE DIF-FERENTIATION OF MONOCLONALGAMMOPATHIES

DEVELOPMENTOFACOST-EFFECTIVE CLINICALASSAY TO SIMUL-TANEOUSLY SCREEN, QUANTITATE AND ISOTYPE M-PROTEINS INREAL-TIME USING MALDI-TOF

SERUM HEAVY LIGHT CHAIN RATIO NORMALIZATION AMONGMULTIPLE MYELOMAPATIENTSACHIEVING SCR

SMOLDERING MULTIPLE MYELOMA: IMPACT OF THE EVOLVINGPATTERN ON EARLY PROGRESSION

EARLY DIAGNOSIS OF MULTIPLE MYELOMA-PROJECT CRAB OFCZECH MYELOMAGROUP(CMG)

ANOVELAPPROACHTOSTUDYEVOLUTIONOFDRUGRESISTANCEAND OPTIMUM THERAPY IN MULTIPLE MYELOMA

POLYMORPHISMS WITHIN IRF4 ENCODING GENE AND ITS SI-GNIFICANCE FOR PATIENTS WITH MULTIPLE MYELOMA

A SIMPLE MODEL TO PREDICT SURVIVAL USING AGE, COMOR-BIDITIES AND FUNCTIONAL STATUS IN PATIENTS WITH MULTIPLEMYELOMA (MM)

DIGITAL PCR FOR MRD DETECTION OF MYELOMA

CLINICAL SIGNIFICANCE OF CIRCULATING PLASMA CELLS INMYELOMA; 6-COLOR MULTIPARAMETER FLOWCYTOMETRYANALYSIS

ANALYSIS OF CD138+ PLASMA CELL PERCENTAGE IN BONEMARROW SECTION USING IMAGEANALYZER : DISCREPANCIES OFBONEMARROWPLASMACELLCOUNT BETWEENASPIRATIONANDBIOPSY SECTION IN MULTIPLE MYELOMA

CLINICALANALYSISOFMULTIPLEMYELOMAPATIENTSWITH BONE-RELATED EXTRAMEDULLARY DISEASE - A LONGITUDINAL STUDYON 834 CONSECUTIVE PATIENTS IN ASINGLE CENTER OF CHINA

EXPLORING THE ROLE OF SHELTERIN COMPLEX AND TE-LOMERASEACTIVITY IN MULTIPLE MYELOMA

PRESENTATION FREE LIGHT CHAIN LEVELS AND AGE ARE THESTRONGEST PREDICTORS OF RENAL FUNCTION IN NEWLYDIAGNOSED MULTIPLE MYELOMAPATIENTS

ASSOCIATION BETWEEN MAGNETIC RESONANCE IMAGINGPATTERNS AND BASELINE DISEASE FEATURES IN MULTIPLEMYELOMA: ANALYZING SURROGATES OF TUMOR MASS ANDBIOLOGY

J.M. Hernandez

D.L. Murray

A.K. Nooka

I. Isola

J. Straub

A. Silva

A. Butrym

P. Milani

S. McAuliffe

M. Fujisawa

N. Lee

D. Shuhui

R. Kumar

P. Yadav

E.K. Mai

PO-016

PO-017

PO-018

PO-019

PO-020

PO-021

PO-022

PO-023

PO-024

PO-025

PO-026

PO-027

PO-028

PO-029

PO-030

TARGETED SEQUENCING OF RELAPSED/REFRACTORY MYELOMAPATIENTS IDENTIFIES AN ENRICHMENT OF MUTATIONS IN MAPKAND CEREBLON PATHWAYS

(GERMLINE) MUTATIONS IN RECEPTOR TYROSINE KINASES: APROGNOSTIC MARKER IN MULTIPLE MYELOMA?

IMPROVED PROGNOSIS IN MULTIPLE MYELOMABYASYSTEMATICCOMBINATORIAL APPROACH: COMBINING EMC92 GENECLASSIFIERWITH ISSRESULTS IN PREDICTIONOFHIGH-AND LOW-RISK MULTIPLE MYELOMA

MINIMALRESIDUALDISEASE INTRANSPLANT INELIGIBLEMYELOMAPATIENTS: RESULTS FROM THE UK NCRI MYELOMAXI TRIAL

RELATIONSHIP BETWEEN PRESENCE OF OSTEOLYTIC LESIONS,CYTOGENETIC FEATURES AND BONE MARROW LEVELS OFCYTOKINES AND CHEMOKINES IN MULTIPLE MYELOMA PATIENTS:ROLE OF CHEMOKINE (C-C MOTIF) LIGAND 20AS NEWMARKEROFBONE DISEASE

PROGNOSTIC IMPACT OF CIRCULATING PLASMA CELLS ONSURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA

ASSESSMENT OF BIOCHEMICAL RESPONSE FOR MULTIPLEMYELOMA (MM) PATIENTS TREATED WITH DARATUMUMAB:PROPOSAL IN CASSIOPEIA STUDY, IFM 2015/01

WHOLE-EPIGENOME ANALYSIS IN MULTIPLE MYELOMA REVEALSDNAHYPERMETHYLATION OF B CELL-SPECIFIC ENHANCERS

THE SPECTRUM AND CLINICAL IMPACT OF EPIGENETIC MODIFIERMUTATIONS IN MYELOMA

MYC PROTEIN EXPRESSION IN MULTIPLE MYELOMA: CLINICOPA-THOLOGICAL FEATURESAND PROGNOSTIC IMPACT

MORNING URINE AS AN ALTERNATIVE TO 24-HOUR URINE ELEC-TROPHORESIS? RENAL LESIONS ASSESSMENT, MONOCLONALPEAK DETECTIONAND QUANTIFICATION COMPARISONS

REVISED INTERNATIONAL STAGING SYSTEM APPLIED TOJAPANESE PATIENTS: A MULTICENTER RETROSPECTIVE COLLA-BORATIVE STUDY OF THE JAPANESE SOCIETY OF MYELOMA

BODY FAT PERCENTAGE AND DISTRIBUTION AS PREDICTIVEFACTORS FOR TREATMENT RESPONSE – A RETROSPECTIVESTUDY IN PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA

HEAVY/LIGHT CHAIN ANALYSIS FOR RESPONSE MONITORING INMULTIPLE MYELOMA PATIENTS: COMPARISONS WITH IMMUNO-FIXATION, SERUM FREE LIGHT CHAIN, AND MULTICOLOR FLOW-CYTOMETRYANALYSIS

K.M. Kortüm

S. Keppler

R. Kuiper

R. De Tute

B. Dalla Palma

M. Granell

H. Caillon

X. Agirre

C. Pawlyn

H.E.H. Møller

P. Boulard

S. Ozaki

J. Groß

K. Matsue

PO-001

PO-002

PO-003

PO-004

PO-006

PO-007

PO-008

PO-009

PO-010

PO-011

PO-012

PO-013

PO-014

PO-015

POSTER SESSION


4342



CYTOGENETIC ABNORMALITIES OF UNDETERMINED CLINICAL SI-NIGICANCE CORRELATE WITH POOR PROGNOSIC FACTORS INMULTIPLE MYELOMA

WHOLE-EXOME SEQUENCING AND TRANSCRIPTOME ANALYSISFOR IGM MULTIPLE MYELOMA

EARLY EVALUATION OF RESPONSE BY SERUM FREE LIGHT CHAIN(FLC) AND HEVYLITE (HLC) IN INTACT IMMUNOGLOBULIN (IIG)MULTIPLE MYELOMA (MM): PREDICTION OF OUTCOME

ASSESSMENTOFTIME FROMONSETOF FIRSTSYMPTOMSTOTHEFINAL DIAGNOSIS OF MULTIPLE MYELOMA (MM) - POSSIBLE RISKSAND FUTURE SOLUTIONS

ASSESSING PROGRESSIVE DISEASE IN MYELOMAPATIENTS WITHWHOLE-BODY DIFFUSION-WEIGHTED IMAGING AT 3.0 T: A PRO-SPECTIVE IMAGING STUDY COMPARING WHOLE BODY T1-WI, T2-STIR-WI AND LABORATORY FINDINGS

MYELOMA MULTIPLE (MM) IGA SUBTYPE. USEFULNESS OFHEAVY/LIGHT IGAK/IGAL QUANTIFICATION FOR DIAGNOSIS ANDFOLLOW-UP

LOW BECLIN-1 EXPRESSION PREDICTS IMPROVED OVERALLSURVIVAL IN PATIENTS TREATED WITH IMMUNE-MODULATORYDRUGS FORMULTIPLEMYELOMAAND IDENTIFIESAUTOPHAGY IN-HIBITION AS A PROMISING POTENTIALLY DRUGGABLE NEW THE-RAPEUTIC TARGET. AN ANALYSIS FROM THE AUSTRIAN MYELOMAREGISTRY (AMR)

NORMALIZATION OF SERUM FREE LIGHT CHAIN RATIO AFTER AU-TOLOGOUSSTEMCELLTRANSPLANTATION INMULTIPLEMYELOMAASAMAJOR CRITERIARESPONSE

RESULTS FROM FIRST PILOT CEQAS FOR MYELOMA GENETICDIAGNOSIS

COMPARISON OF FREELITE AND N LATEX SERUM FREE LIGHTCHAINASSAYS IN SUBJECTSWITH ENDSTAGERENALDISEASEONHAEMODIALYSIS

CLONAL CHANGES ARE FREQUENTLY DETECTED BY CY-TOPLASMIC IMMUNOGLOBULIN-FLUORESCENCE IN SITU HYBRI-DIZATION WITH PROGRESSION OF MULTIPLE MYELOMA

PROGNOSTIC VALUEOFTHE INVERSEPLATELET-TO-LYMPHOCYTERATIO (IPLR) IN PATIENTS WITH MULTIPLE MYELOMA WHO WERETREATED UPFRONTWITHANOVEL-AGENT-CONTAINING REGIMEN

EARLY MORTALITY IN THE PATIENTS WITH MULTIPLE MYELOMAWHO WERE TREATED UPFRONT WITH A NOVEL AGENT-CONTAINING REGIMEN

Y.K. Lee

D. Ryu

S. SavaryBélanger

G. Graziani

S. Pans

M. AndradeCampos

W. Willenbacher

S. Gentili

P.J. Talley

A. Kennard

S. Hwang

J.J. Lee

J.J. Lee

PO-044

PO-045

PO-046

PO-047

PO-048

PO-049

PO-050

PO-051

PO-052

PO-053

PO-054

PO-055

PO-056

COMPARISON OF MINIMAL RESIDUAL DISEASE DETECTION INMULTIPLE MYELOMA BETWEEN MULTIPARAMETER FLOWCYTOMETRYAND DEEP-SEQUENCING

GAH SCALE IS ASIMPLE, COMPREHENSIVEASSESSMENT TOOL INOLDER PATIENTS WITH HEMATOLOGICAL MALIGNANCIES THATSHOWS MORTALITY PREDICTION CAPACITIES

OUTCOME OF PATIENTS WITH EXTRAMEDULLARY PLA-SMACYTOMAS (EMPS) INCLUDED IN A PHASE III PETHEMA/GEMSTUDYOF INDUCTION THERAPY PRIORAUTOLOGOUS STEM CELLTRANSPLANTATION (ASCT) IN MULTIPLE MYELOMA (MM)

RELATIONSHIP OF SERUM LEVELS OF SELECTED BIOLOGICAL IN-DICATORS AND CYTOGENETIC ABNORMALITIES IN MULTIPLEMYELOMA

INFLUENCE OF CRBN, IKZF1, AND IKZF3 EXPRESSION ONOUTCOME IN LENALIDOMIDE TREATED NEWLY DIAGNOSEDMULTIPLE MYELOMAPATIENTS

RESPONSE AND EARLY RELAPSE ASSESSMENT IN MULTIPLEMYELOMA TREATED WITH BORTEZOMIB: ROLE OF HEAVY/LIGHT-CHAIN IMMUNEASSAY

RISK FACTORS OF DEVELOPING SYMPTOMATIC MYELOMA FROMMGUS: ANALYSIS IN OUR HOSPITAL

DIFFUSIONWEIGHTEDWHOLE BODYMRI FOR EARLYEVALUATIONOF RESPONSE IN MULTIPLE MYELOMA

MYELOMABONE LESIONSONWHOLE-BODYDIFFUSION-WEIGHTEDMAGNETIC RESONANCE IMAGING AT 3.0 T: CHARACTERIZATIONAND COMPARISON OF APPARENT DIFFUSION COEFFICIENT ANDB1000 VALUE ON 2 DIFFERENT MRI PLATFORMS OF THE SAMEVENDOR

RENAL FUNCTION AND AGE AT PRESENTATION AND SERUM FREELIGHT CHAIN RESPONSE AT POST-INDUCTION PREDICT RENALOUTCOME

PREVALENCE OF OLIGOCLONAL BANDS IN MULTIPLE MYELOMAPATIENTS WHO ACHIEVED AT LEAST VERY GOOD PARTIALRESPONSE AFTER TREATMENT WITH STANDARD OR HIGH DOSECHEMOTHERAPY- FINALANALYSIS

DETECTING EARLY RELAPSE IN MULTIPLE MYELOMA (MM) AFTERASCT: USEFULNESS OF IMMUNEASSAYS

ABSOLUTE LYMPHOCYTE COUNT AS A PROGNOSTIC MARKER INNEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED INTHE ERAOF NOVELAGENTS

H. Takamatsu

J. de la Rubia

R. Jiménez

P. Pusciznova

J. Krönke

M. AndradeCampos

M. Itagaki

G. Barilà

S. Pans

P. Yadav

L. Soares VieiraDa Silva

M. AndradeCampos

C. Suriu

PO-031

PO-032

PO-033

PO-034

PO-035

PO-036

PO-037

PO-038

PO-039

PO-040

PO-041

PO-042

PO-043


4544

CAPILLARY ZONE ELECTROPHORESIS IS A VERY SENSITIVEMETHODFORDIAGNOSISANDMONITORINGOFMULTIPLECLONESOF MULTIPLE MYELOMA, OTHER PLASMA CELL DYSCRASIAS ANDLYMPHOPROLIFERATIVE DISORDERS

PROSPECTIVEASSESSMENTOFACOMORBIDITYANDFUNCTIONALGERIATRIC ASSESSMENT (CF-GA), INCLUDING THE REVISEDFREIBURG COMORBIDITY INDEX (RFCI) IN MM PATIENTS (PTS)

NOVEL PROGNOSTIC MODEL OF COMBINATION NEUTROPHIL-LYMPHOCYTERATIO, PLATELETCOUNT,ANDC-REACTIVE PROTEINMIGHT PREDICT PROGNOSIS OF PATIENTS WITH NEWLYDIAGNOSED MULTIPLE MYELOMA

PROGNOSTIC VALUE OF FLOW CYTOMETRIC ANTIGEN EX-PRESSION PATTERN ON BONE MARROW NEOPLASTIC PLASMACELLS FROM MULTIPLE MYELOMAPATIENTS

TRANSLOCATIONT(8;14) INMULTIPLEMYELOMADEFINESPATIENTSWITH VERY POOR PROGNOSIS – SINGLE CENTRE EXPERIENCE

IMWG ´03 VS ´14 DIAGNOSTIC CRITERIA FOR SYMPTOMATICMULTIPLE MYELOMA: WILLWE HAVE TO SOLVEAPROBLEM?

CLINICAL VALUE OF SERUM FREE LIGH CHAINASSAY INALGERIANNEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING HIGHDOSE THERAPY

A CYTOF-BASED APPROACH TO DETECT MINIMAL RESIDUALDISEASE IN PATIENTS WITH MULTIPLE MYELOMA

FRAILTY BURDEN IS ASSOCIATED WITH SURVIVAL IN ELDERLYPATIENTS WITH DIAGNOSIS OF MULTIPLE MYELOMA

MYD88 L265PMUTATIONSARECORRELATEDWITH 6QDELETION INKOREAN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA

ALKALINE PHOSPHATASE (ALP) LEVELS IN MULTIPLE MYELOMA(MM) AND CANCER WITH BONE LESIONS: IS THERE ANYDIFFERENCE?

CENTRAL NERVOUS SYSTEM INFILTRATION BY PLASMA CELLS:RARE OCCURRENCE IN MULTIPLE MYELOMAPATIENTS

PRONGNOSTIC IMPLICATION OF CYTOGENETIC ABNOMALITIESFOR NEWLYDIAGNOSEDMULIPLE MYELOMA IN YOUNG PATIENTS:TUNISIAN MONOCENTER EXPERIENCE

HIGH SERUM LACTATE DEHYDROGENASE LEVEL USED AS APROGNOSTIC FACTOR IN MULTIPLE MYELOMA

P.P. Kotoucek

A. Zober

D.S. Kim

Y. Meddour

T. Pika

S. Cerdá

Y. Meddour

A. Ghosh

N. Schütz

J.A. Kim

O. Annibali

A. Jorge

M. Zarrouk

D. Stoumbos

PO-073

PO-074

PO-075

PO-076

PO-077

PO-078

PO-079

PO-080

PO-081

PO-082

PO-083

PO-084

PO-085

PO-086

UTILITYOFTHEHEAVY/LIGHTCHAINASSAY INTHEEVALUATIONOFCOMPLETE RESPONSE TO THERAPY IN MULTIPLE MYELOMAPATIENTS

MULTIPLE MYELOMA AS A SECOND PRIMARY MALIGNANCY; ONEFOURTH OF PATIENTS HAD PRIOR HISTORY OF OTHER MA-LIGNANCES

THE IMPACT OF DIALYSIS-DEPENDENT ACUTE KIDNEY INJURY ONMORTALITY IN MYELOMA: FINDINGS FROM ENGLAND HOSPITALEPISODE STATISTICS DATA

EXPIRATION: INSPIRATION RATIO AS A PROGNOSTIC FACTOR INSYSTEMICALAMYLOIDOSIS

BASELINE F-18 FDGPETUPTAKEOFBONEMARROWASASURVIVALPREDICTOR IN PATIENTS WITH MULTIPLE MYELOMA

INFLUENCE OF KIDNEY HISTOLOGY ON PROGNOSIS IN MULTIPLEMYELOMA

THE CLINICAL SIGNIFICANCE OF DECREASING CD138 POSITIVEMYELOMACELLS IN BONE MARROW

A SINGLE CENTRE RETROSPECTIVE ANALYSIS OF DIAGNOSTICFLUORESCENCE IN SITU HYBRIDISATION REVEALS DISTINCTGROUPS OF CYTOGENETIC ABNORMALITIES, WHICH AFFECTEARLY SURVIVAL OF NEWMYELOMADIAGNOSIS

REVEALING GENOMIC PROFILE THAT UNDERLIES TROPISM OFMYELOMACELLS USINGWHOLE EXOME SEQUENCING

COMPARISON OF BONE MARROWASPIRATE AND BONE MARROWBIOPSY IN THE WORKUP OF PATIENTS WITH MULTIPLE MYELOMA

CHARACTERISTICS OF MYELOMA (MM) PATIENTS (PTS) WITHCENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT

HIGHEXPRESSIONOFAF1Q ISANADVERSEPROGNOSTIC FACTORIN MULTIPLE MYELOMA PATIENTS TREATED WITH AUTOLOGOUSSTEM CELL TRANSPLANTATION

EXPRESSION OF MTH1 IN MULTIPLE MYELOMA AND ITS RELA-TIONSHIP WITH THERAPEUTIC RESPONSE

CAST NEPHROPATHY VS ACUTE TUBULAR NECROSIS IN NEWLYDIAGNOSED MULTIPLE MYELOMA: ACOMPARATIVE STUDY

COMPARISON OF WHOLE-BODY LOW-DOSE COMPUTED TO-MOGRAPHYAND CONVENTIONAL RADIOGRAPHY IN THE STAGINGOF MULTIPLE MYELOMA

THE SIGNIFICANCE OF HEVYLITE TEST FOR DETERMINATION OFPROGNOSIS IN PATIENTS WITH ASYMPTOMATIC MULTIPLEMYELOMA - THE RESULTS OFANEW CMG PROJECT

J. Batini

N. Nishimura

M. Cook

W.K. Jeong

E. Lee

R. Bergner

M. Ikeda

I. Walker

S.S. Yoon

J. Dallemagne

T.A. Richards

S. Hagiwara

H. Zhou

I. Jaffer Sathick

H. Plonkova

V. Maisnar

PO-057

PO-058

PO-059

PO-060

PO-061

PO-062

PO-063

PO-064

PO-065

PO-066

PO-067

PO-068

PO-069

PO-070

PO-071

PO-072

4746



FRONTLINE THERAPY FOR MULTIPLE MYELOMA (MM) IN REAL-WORLD CLINICAL PRACTICE: RESULTS FROM THE THIRD INTERIMANALYSIS OF THE MULTINATIONAL, NON-INTERVENTIONAL, OB-SERVATIONAL EMMOS STUDY

CENTRAL NERVOUS SYSTEM INVOLVEMENT BY MULTIPLEMYELOMA:AMULTI-INSTITUTIONALRETROSPECTIVESTUDYOF 172PATIENTS

IMPROVED TUMOR RESPONSE AND SURVIVAL OUTCOMES WITHPOST-TRANSPLANT BORTEZOMIB (BTZ) CONSOLIDATION VERSUSOBSERVATION (OBS)ALONE IN PATIENTSWITHNEWLYDIAGNOSEDMULTIPLEMYELOMA (MM): RESULTS FROMARANDOMIZED, OPEN-LABEL, MULTICENTER, PARALLEL-GROUP PHASE 2 STUDY

CONTINUOUS TREATMENT WITH LENALIDOMIDE AND LOW-DOSEDEXAMETHASONE FOR PATIENTS WITH TRANSPLANT-INELIGIBLENEWLY DIAGNOSED MULTIPLE MYELOMA IN THE FIRST TRIAL:IMPACT OFAGE

IMPROVEMENT OF QUALITY OF RESPONSE AFTER ADDITIONALTHERAPYBEFOREAUTOLOGOUSSTEMCELLTRANSPLANT IS NOTTRANSLATED IN IMPROVEMENT OF GLOBAL OUTCOME OFMULTIPLE MYELOMAPATIENTS

EFFECTOF HIGH DOSEMELPHALANADMINISTRATION SCHEDULE:COMPARISON BETWEEN 1-DAY AND 2-DAY DOSE FOR MYELOMACONDITIONING REGIMEN

A2-STAGE PHASE II STUDYOF PANOBINOSTATCONSOLIDATION INMYELOMA PATIENTS WITH < CR FOLLOWING HIGH-DOSE CHE-MOTHERAPY (HDT) CONDITIONEDAUTOLOGOUSSTEMCELLTRAN-SPLANTATION (ASCT)

LEOPARD: A PHASE II STUDY OF POST AUTOLOGOUS STEM CELLTRANSPLANTATION (ASCT) MAINTENANCE LENALIDOMIDE ANDPREDNISOLONE FOR MYELOMA (MM), INCORPORATING MINIMALRESIDUAL DISEASE (MRD) ASSESSMENTS

FAVORABLE LONG-TERM SURVIVAL OF PATIENTS WITH MULTIPLEMYELOMA USING A FRONTLINE TANDEM APPROACH WITH AU-TOLOGOUS AND NONMYELOABLATIVE ALLOGENEIC TRAN-SPLANTATION

UPDATEDOVERALLSURVIVAL (OS)ANALYSISOFTHE FIRSTSTUDY:LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD)CONTINUOUS VS MELPHALAN, PREDNISONE, AND THALIDOMIDE(MPT) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLEMYELOMA (NDMM)

HEAVY/LIGHT CHAIN ASSAYS IDENTIFY MONOCLONAL INTACT IM-MUNOGLOBULIN IN ‘LIGHT CHAIN ONLY’ PATIENTS

M. Mohty

A. Jurczyszyn

O. Sezer

C. Hulin

A. Natale

P. Lawasut

A. Kalff

A. Kalff

I. Ahmad

T. Facon

H. Ludwig

PO-087

PO-088

PO-089

PO-090

PO-091

PO-092

PO-093

PO-094

PO-095

PO-096

PO-097

PRETRANSPLANT INDUCTION WITH VTD (BORTEZOMIB/THALIDOMIDE /DEXAMETHASONE) SIGNIFICANTLY IMPROVES PFS:LONG-TERMRESULTSOFTHERANDOMIZEDPHASE3PETHEMA/GEMSTUDY

THEQUADRUPLETKCRD (CARFILZOMIB, CYCLOPHOSPHAMIDE, LE-NALIDOMIDE, AND DEXAMETHASONE) IS SAFE AND WELLTOLERATED AS INDUCTION THERAPY FOR NEWLY DIAGNOSED,TRANSPLANT ELIGIBLE, MYELOMAPATIENTS

INDUCTION REGIMENS FOR AUTOLOGOUS TRANSPLANT (AHCT)ELIGIBLE MYELOMA (MM) PATIENTS (PTS) – DOUBLETS ORTRIPLETSANDWHICH TRIPLET?

MYELOMACANADARESEARCH NETWORK (MCRN) 001 TRIALWITHINTRAVENOUS (IV) BUSULFAN + MELPHALAN (BUMEL) ASENHANCED CONDITIONING, FOLLOWED BY LENALIDOMIDE (LEN)MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)PATIENTS (PTS): FIRST RESULTS OF MINIMAL RESIDUAL DISEASE(MRD) AND HEVYLITE(TM) CHAIN (HLC) ASSAYS AT DAY 100 POSTAUTOLOGOUS STEM CELL TRANSPLANT (ASCT)

IMMUNOHISTOCHEMICAL (IHC) BIOMARKERS ASSOCIATED WITHRESPONSEANDSURVIVALFOLLOWING LENALIDOMIDEANDPRED-NISOLONE MAINTENANCE POST-ASCT IN PATIENTS WITH MM: ANEXPLORATORY, HYPOTHESIS GENERATING SUB-STUDY OF THELEOPARD TRIAL

IMPACT OF COMPLETE RESPONSE ON PROGRESSION-FREESURVIVAL AND OVERALL SURVIVAL IN NEWLY DIAGNOSEDMYELOMA PATIENTS TREATED WITH AUTOLOGOUS STEM CELLTRANSPLANTATION OR CONVENTIONAL CHEMOTHERAPY:RESULTS OFAPOOLEDANALYSIS OF 5 PHASE III TRIALS

CONTINUOUS TREATMENT IMPROVES SURVIVAL OF NEWLYDIAGNOSEDMULTIPLEMYELOMAPATIENTSACHIEVINGCOMPLETERESPONSE: DATAFROM5PHASE III TRIALS INCLUDINGYOUNGANDELDERLY PATIENTS

THETREATMENT (TX) OF PATIENTS (PTS)WITHNEWLYDIAGNOSEDMULTIPLE MYELOMA (NDMM) INELIGIBLE FOR TRANSPLANT: A SY-STEMATIC LITERATURE REVIEWAND NETWORK META-ANALYSIS

MULTIPLE MYELOMA PATIENTS WITH UNMEASURABLE DISEASEBENEFIT LESS FROM BORTEZOMIB-BASED REGIMENS

IMPACT OF RESPONSE IN PATIENTS (PTS) WITH STEM CELLTRANSPLANT (SCT)-INELIGIBLE NEWLY DIAGNOSED MULTIPLEMYELOMA (NDMM) TREATEDWITH CONTINUOUS LENALIDOMIDE +LOW-DOSE DEXAMETHASONE (RD) IN THE FIRST TRIAL

L. Rosiñol

C. Pawlyn

P. Hari

D. Reece

A. Kalff

R. Mina

C. Cerrato

K. Weisel

X. Qin

N. Bahlis

BP-011

BP-012

BP-013

BP-014

BP-015

BP-016

BP-017

BP-018

BP-019

BP-020

2. Multiple Myeloma Therapy in Newly Diagnosed Patients including Transplantation

POSTER DISCUSSION SESSIONChairman: Andrzej J. Jakubowiak

POSTER SESSION

4948



TOTALMARROW IRRADIATION (TMI)WITHHELICALTOMOTHERAPYAND PERIPHERAL BLOOD PROGENITOR CELL RESCUE (PBPC)FOLLOWINGHIGH-DOSEMELPHALAN (MEL)ANDPBPCAS PARTOFTANDEM AUTOLOGOUS TRANSPLANT (TAT) FOR PATIENTS WITHMULTIPLE MYELOMA

APPRAISAL OF IGM KAPPA/IGM LAMBDA VARIATIONS USINGHEVYLITE® AFTER RITUXIMAB AS CONSOLIDATION THERAPY INPATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA

SAFETY AND EFFICACY OF FIRST-LINE TREATMENT WITH DO-XORUBICIN, CYCLOPHOSPHAMIDE, BORTEZOMIB, DEXA-METHASONE AND LENALIDOMIDE (ACVDL) IN NEWLY DIAGNOSEDMULTIPLE MYELOMAPATIENTS OFALLAGES

OUTCOME OF T(4;14) IN MULTIPLE MYELOMA – PRINCESSMARGARET CANCER CENTRE EXPERIENCE OVER THE LAST 10YEARS

AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FORMULTIPLE MYELOMA (MM): PREDICTORS OF LONG TERMOUTCOME

LOW DOSE DEXAMETHASONE PLUS LENALIDOMIDE (LEN-DEXA)VERSUSTHALIDOMIDE (THAL-DEXA)AS INDUCTION THERAPY FORNEWLY DIAGNOSED MULTIPLE MYELOMA: A PHASE III,RANDOMIZED STUDY

LENALIDOMIDE MAINTENANCE CAUSES PERSISTENCE OFABNORMAL PROTEIN BANDS IN MULTIPLE MYELOMA PATIENTSAFTER INDUCTION WITH NEW DRUGS AND AUTOLOGOUS BONEMARROW TRANSPLANTATION

AUTOLOGOUS STEMCELLTRANSPLANTATION (ASCT) IN PATIENTSWITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) OVER 65YEARS

EARLY CLINICAL OUTCOMES AND LONG-TERM SURVIVAL IN MMPATIENTS UNDERGOING AUTOLOGOUS HSCT AFTER MELPHALAN200 MG/M2 CONDITIONING WITHOUT WEIGHT-BASED DOSE-AD-JUSTMENTARE UNAFFECTED BY BODYMASS INDEX

PROGNOSTIC FACTORS FOR OVERALL AND PROGRESSION-FREESURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOINGSINGLEAUTO-SCT

OUTCOME AFTER AUTOLOGOUS STEM CELL TRANSPLANTATIONFORMYELOMAIN PATIENTS BEYOND 60, 65AND 70YEARSOFAGE:ARETROSPECTIVEANALYSIS FROM THE GERMAN REGISTRY FORSTEM CELL TRANSPLANTATION (DRST)

A MULTI-CENTRE REVIEW OF MOBILISATION STRATEGIES POSTUPFRONTVCD INDUCTION INMULTIPLEMYELOMA: ISG-CSFALONESUFFICIENT?

G. Somlo

J.R. Eveillard

K.T. Andersen

V. Kukreti

L. Kumar

L. Kumar

B. Gamberi

S. Cerdá

A. Roque

V.H. JimenezZepeda

M. Merz

C.C. Chua

PO-110

PO-111

PO-112

PO-113

PO-114

PO-115

PO-116

PO-117

PO-118

PO-119

PO-120

PO-121

BORTEZOMIB BASED THERAPIES AND HIGH CUT OFF FILTERDYALYSIS (HCO)ARE EFFECTIVE INMULTIPLEMYELOMAPATIENTSWITH END STAGE RENAL FAILURE

SUBCUTANEOUS BORTEZOMIB PLUS MELPHALAN ANDPREDNISONE (VMP) IN NON-TRANSPLANT ELIGIBLE NEWLYDIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS: SPANISH EX-PERIENCE

SERUM FREE LIGHT CHAIN CHANGES OFFER A MORE ACCURATEASSESSMENT OF RESPONSE TO THERAPY THAN URINE BENCEJONES PROTEIN EXCRETION MEASUREMENTS IN MULTIPLEMYELOMA

EFFICACY OF NEW DRUGS AS TREATMENT BEFORE SINGLE ORTANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLYDIAGNOSED MULTIPLE MYELOMAPATIENTS

CLINICALOUTCOMES IN PATIENTS (PTS)WITH NEWLYDIAGNOSEDMULTIPLE MYELOMA (NDMM) AND T(4;14) IN THE CONNECT MM®REGISTRY

A RANDOMIZED PHASE II STUDY OF STEM CELL MOBILIZATIONWITHCYCLOPHOSPHAMIDE +G-CSF VERSUSG-CSFALONEAFTERLENALIDOMIDE-BASED INDUCTION IN MULTIPLE MYELOMA

LONGTERMCRYOPRESERVEDAUTOLOGOUSBLOODSTEMCELLSFOR SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION(ASCT) IN RELAPSED MULTIPLE MYELOMA (MM) PATIENTS

CONTINUOUS LENALIDOMIDE AND LOW-DOSE DEXAMETHASONEFOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSEDMULTIPLE MYELOMAAND RENAL IMPAIRMENT IN THE FIRST TRIAL

RECOMBINANT MAGE-A3 PROTEIN IMMUNOTHERAPY AND PE-RIPHERAL BLOOD LYMPHOCYTE (PBL) RECONSTITUTION INDUCESTRONG ANTIGEN-SPECIFIC HUMORAL AND CELLULAR IMMUNERESPONSES IN PATIENTSUNDERGOINGAUTOLOGOUSSTEMCELLTRANSPLANTATION (ASCT) FOR CONSOLIDATION OF MULTIPLEMYELOMA (MM)

LONG-TERM EFFICACY OF SEQUENTIAL VINCRISTINE,ADRIAMYCIN, AND DEXAMETHASONE (VAD) AND BORTEZOMIB,THALIDOMIDE, AND DEXAMETHASONE (VTD) AS INDUCTION CHE-MOTHERAPY FOLLOWED BY HIGH-DOSE MELPHALAN WITH AU-TOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT) ANDBORTEZOMIB CONSOLIDATION: A FOLLOW-UP STUDY OF KMM51

IMPACT OF ANTI-MYELOMA IDUCTION TREATMENT AND OTHERPREDICTIVE FACTORSONSTEMCELLHARVESTING, IN THENOVEL-AGENT ERA

CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE(CYBORD) INDUCTION: IMPACTON RESPONSE RATEAND MDR NE-GATIVITY FOR PATIENTS WITH MULTIPLE MYELOMAUNDERGOINGSINGLEAUTO-SCT

A. Gozzetti

F. De Arriba

T. Dejoie

S. Grammatico

J.J. Shah

R. Silvennoinen

N. Areethamsiri-kul

M. Dimopoulos

N. Lendvai

J. Shin

C. Lalayanni

V.H. JimenezZepeda

PO-098

PO-099

PO-100

PO-101

PO-102

PO-103

PO-104

PO-105

PO-106

PO-107

PO-108

PO-109

5150



THE TREATMENT STRATEGIES IN PATIENTS WITH PARTIALRESPONSE TO HIGH-DOSE CHEMOTHERAPYANDASCT

ENGRAFTMENT SYNDROME DURING AUTO HSCT IN PLASMACELLDISORDERS: RETROSPECTIVE ANALYSIS OF CONSECUTIVECASES FROMATERTIARY CARE CENTRE

RETROSPECTIVEANALYSIS OF THE IMPACTOF KIDNEY FUNCTIONON THE OUTCOMES OF FIRST AUTOGRAFTS FOR DE NOVOMYELOMAPATIENTS IN THE ERAOF NOVELAGENTS

COMPARISONOFTHEPERFORMANCEOFTHENEWLYDEVELOPEDIGG HEAVY CHAIN/LIGHT CHAIN IMMUNOASSAYS WITH SERUMPROTEIN ELECTROPHORESIS FOR MONITORING IGG MULTIPLEMYELOMAPATIENTS

IDENTIFICATION OF PREDICTOR FACTORS FOR EARLY RELAPSE(ER) IN PATIENTS WITH MM UNDERGOING SINGLEAUTO-SCT

PHASE 1 STUDYOFELOTUZUMAB (ELO) IN COMBINATIONWITH LE-NALIDOMIDE/DEXAMETHASONE (LEN/DEX) IN JAPANESE PATIENTS(PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA(RRMM) AND LONG-TERM FOLLOW-UP

SUBCUTANEOUS ADMINISTRATION OF BORTEZOMIB SIGNI-FICANTLY DECREASEDAND DELAYED THE DEVELOPMENT OF PE-RIPHERAL NEUROPATHY IN PATIENTS WITH NEWLY DIAGNOSEDMULTIPLE MYELOMA

MELPHALAN 140MG/M"2" SIGNIFICANTLY REDUCES 5 YEAR PRO-GRESSION FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTSRECEIVING A PERIPHERAL BLOOD AUTOLOGOUS STEM CELLTRANSPLANT COMPAREDWITH MELPHALAN 200MG/M"2"

REGISTRY BASED RETROSPECTIVEANALYSIS OF BENDAMUSTINECONDITIONED SECOND AUTOLOGOUS HEMATOPOIETIC STEMCELL TRANSPLANTS FOR RELAPSED MYELOMA

THE EMPEROR IS NAKED: THE QUALITY OF RESPONSE TO FIRST-LINE THERAPY IS NOT RELATED TO SURVIVAL IN MULTIPLEMYELOMA (MM) PATIENTS

PHASE 2 STUDYUSING INTRAVENOUSBUSULFANANDMELPHALANCONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRAN-SPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: INTERIMANALYSIS (KMM150)

INCREASED INCIDENCE OF SYMPTOMATIC POSTURAL HY-POTENSION INMULTIPLEMYELOMAPATIENTSTREATEDWITHSUB-CUTANEOUS BORTEZOMIB

HEALTH RESOURCE UTILIZATION WITH CONTINUOUS LENA-LIDOMIDE TREATMENT (TX) IN ELDERLY PATIENTS (PTS) WITHNEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

S.K. Park

R. Pramanik

L. Floro

O. Berlanga

V.H. JimenezZepeda

T. Chou

Y. Xu

C. Attwood

L. Floro

I. Hardan

J.J. Lee

S. Ahmed

K. Weisel

PO-136

PO-137

PO-138

PO-139

PO-140

PO-141

PO-142

PO-143

PO-144

PO-145

PO-146

PO-147

PO-148

SKIN INVOLVEMENT BY MULTIPLE MYELOMA: A MULTI-INSTI-TUTIONAL RETROSPECTIVE STUDY OF 53 PATIENTS

A RESPONSE ADAPTED APPROACH TO INDUCTION TREATMENTYIELDS ACCEPTABLE OUTCOME IN PATIENTS WITH MULTIPLEMYELOMA (MM) UNDERGOING AUTOLOGOUS STEM CELL TRAN-SPLANTATION (ASCT)

VCD, VD AND VMP IN FRONT LINE TREATMENT: OUTCOMES FROMTHAI MYELOMA WORKING GROUP – PATIENT ASSISTANCEPROGRAM (TMWG-PAP)

NUMBEROFCD34 +CELLSCOLLECTEDBETWEENTWODIFFERENTMOBILIZATIONSCHEDULES INMULTIPLEMYELOMAPATIENTSWITHCTD INDUCTION AND CANDIDATES FOR AUTOLOGOUSTRANSPLANT OF HEMATOPOIETIC PROGENITOR CELLS

PROGRESSION-FREE SURVIVALFOLLOWINGAUTOLOGOUSTRAN-SPLANTATION FORMULTIPLEMYELOMAIS NOTCOMPROMISEDBYTHE USE OF DOSE-ADJUSTED MELPHALAN

SUCCESSFULASSESSMENTANDEDUCATIONAL INTERVENTIONOFGUIDELINE-BASED APPROACHES FOR THE MANAGEMENT OFMULTIPLE MYELOMA

THE EFFICACY AND SAFETY OF HIGH DOSE MELPHARAN PLUSBORTEZOMIB FOLLOWED BY AUTO PBSCT IN ELDERLY MULTIPLEMYELOMAPATIENTS

COMPARISONOFTHEPERFORMANCEOFTHENEWLYDEVELOPEDIGA HEAVY CHAIN/LIGHT CHAIN IMMUNOASSAYS WITH SERUMPROTEIN ELECTROPHORESIS AND NEPHELOMETRIC TOTAL IGAMEASUREMENTS FOR MONITORING IGA MULTIPLE MYELOMAPATIENTS

PRE TRANSPLANT ACHIEVEMENT OF VERY GOOD PARTIALRESPONSE RESULTS IN IMPROVED SURVIVAL IN MYELOMA

EARLY PROGRESSION (WITHIN 12 MONTHS) AFTER AUTOLOGOUSSTEM-CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLEMYELOMA

CLINICAL FEATURES AND OUTCOMES AFTER AUTO-SCT INPATIENTS WITH MULTIPLE MYELOMAAND RENAL IMPAIRMENT

STEM CELL MOBILIZATION AND AUTOLOGOUS STEM CELL TRAN-SPLANTATION AFTER PRETREATMENT CONSISTING OF BEN-DAMUSTINE, PREDNISONEANDBORTEZOMIB (BPV) IN 35 PATIENTSWITH NEWLY DIAGNOSED/UNTREATED MULTIPLE MYELOMA

SERUM FREE LIGHT CHAIN ASSAYS, NOT TOTAL LIGHT CHAINASSAYS, ARE THE STANDARD OF CARE IN THE ASSESSMENT OFMONOCLONALGAMMOPATHIES

HEAVY CHAIN/ LIGHT CHAIN IMMUNOASSAYS FOR MONITORINGOLIGOSECRETORYMULTIPLE MYELOMAPATIENTS

A. Jurczyszyn

G.L. Shah

P. Lawasut

E. de QueirozCrusoe

J. Sangha

E.S. Van Laar

N. Takezako

O. Berlanga

O.S. Yeu

S.H. Lim

H. Ryu

W. Poenisch

V. Hungria

O. Berlanga

PO-122

PO-123

PO-124

PO-125

PO-126

PO-127

PO-128

PO-129

PO-130

PO-131

PO-132

PO-133

PO-134

PO-135

5352



A PROSPECTIVE PHASE II TRIAL OF LENALIDOMIDE AND DEXA-METHASONE (LEN-DEX) IN POEMS SYNDROME

AUTOLOGOUS STEMCELLTRANSPLANTATION (ASCT) IN PATIENTSWITH POEMS SYNDROME RESULTS IN DURABLE SYMPTOMATICDISEASE CONTROL: A RETROSPECTIVE STUDY OF THE PLASMACELL DISORDER SUB-COMMITTEE OF THE CHRONIC MALI-GNANCIES WORKING PARTY OF THE EBMT

SAFETY AND EFFICACY OF CARFILZOMIB (CFZ) IN PREVIOUSLY-TREATED SYSTEMIC LIGHT-CHAIN (AL) AMYLOIDOSIS

A RANDOMIZED PHASE III TRIAL OF MELPHALAN AND DEXA-METHASONE (MDEX) VERSUS BORTEZOMIB, MELPHALANAND DE-XAMETHASONE (BMDEX) FOR UNTREATED PATIENTS WITH ALAMYLOIDOSIS

INTERIMANALYSIS OFALCHEMY–APROSPECTIVE STUDYOF 1000PATIENTS WITH SYSTEMICALAMYLOIDOSIS

PHASE 3 STUDYOF THE ORALPROTEASOME INHIBITOR IXAZOMIBFORRELAPSED/REFRACTORYALAMYLOIDOSIS: TOURMALINE-AL1

ANALYSIS OF SECOND PRIMARYMALIGNANCIES (SPMS) IN CALGB(ALLIANCE)/ECOG/BMT CTN 100104

SYSTEMATIC CLASSIFICATION OF DEATH CAUSES IN MULTIPLEMYELOMAPATIENTS TREATEDWITH HIGH-DOSE THERAPY

COMBINING EFFICACY AND TOXICITY EFFECT SIZES FROMRANDOMIZED CLINICAL TRIALS (RCTS) INTO AN INTERPRETABLEQUALITY-ADJUSTED EFFECT SIZE ESTIMATE IN PATIENTS WITHMULTIPLE MYELOMA (MM)

IMPACTOFNOVELTHERAPIESONMULTIPLEMYELOMASURVIVAL–CURRENTAND FUTURE OUTCOMES

GUIDELINES FOR THE CORRECT DETERMINATION OF SECONDPRIMARYMALIGNANCIES IN MYELOMATRIALS

LEVELS OF DISCORDANCE BETWEEN PATIENTS’AND PHYSICIANS’PERCEPTIONS OF PATIENTS’ HEALTH-RELATED QUALITY OF LIFE(HRQOL) IN RELAPSED/REFRACTORYMULTIPLEMYELOMA(RRMM)– ACROSS-CULTURAL PERSPECTIVE

ORTHOTOPICHEARTTRANSPLANTFACILITATEDAUTOLOGOUSHE-MATOPOIETIC STEMCELLTRANSPLANTATION IN LIGHT-CHAINAMY-LOIDOSIS

A. Jaccard

G. Cook

A.D. Cohen

E. Kastritis

A. Wechalekar

G. Merlini

S.A. Holstein

E.M. Haas

B. Major

A. Drawid

J. Jones

X. Leleu

R.T. Kamble

BP-021

BP-022

BP-023

BP-024

BP-025

BP-026

BP-027

BP-028

BP-029

BP-030

PO-164

PO-165

PO-166

SUCCESFUL STEM CELL COLLECTION IN NEWLY DIAGNOSEDMULTIPLE MYELOMA (NDMM) PATIENTS OVER 65 YEARS OLD

AUTOLOGOUS STEM CELLCOLLECTIONAFTER BIOSIMILAR G-CSF(ZARZIO®) COMPARED TO ORIGINAL G-CSF (NEUPOGEN®) INMULTIPLE MYELOMAPATIENTS

SUCCESSFUL TREATMENT OF PATIENTS WITH NEWLYDIAGNOSED/UNTREATED LIGHT CHAIN MULTIPLE MYELOMAWITHA COMBINATION OF BENDAMUSTINE; PREDNISONE ANDBORTEZOMIB (BPV)

COMPARISON OF THE CLINICAL SENSITIVITY OF TWO FREE LIGHTCHAINASSAYS INACOHORTOF LIGHTCHAIN MULTIPLE MYELOMAPATIENTS

FRONTLINE TREATMENT SCHEME VTD (BORTEZOMIB/ THA-LIDOMIDE/DEXAMETHASONE) IN PATIENTS WITH MULTIPLEMYELOMATRANSPLANT CANDIDATESAT OUR CENTER

AUTOLOGOUS STEM CELL TRANSPLANTATION FORALAMYLOIDOSIS

DAY 4 PERIPHERALBLOOD STEM CELLCOLLECTION IN MYELOMAPATIENTS IS FEASIBLEANDAND COST-EFFECTIVE INAMAJORITYOF PATIENTS

EVALUATION OF THE NOVEL HEVYLITE® IGM KAPPA/IGM LAMBDAASSAYS IN WALDENSTRÖM’S MACROGLOBULINEMIA PATIENTSAFTER RITUXIMAB CONSOLIDATION THERAPY

THE EVOLVING ROLE OF STEM CELL TRANSPLANT IN MULTIPLEMYELOMA: A SINGLE INSTITUTION STUDY

PREDICTION OF POOR MOBILIZATION OF PERIPHERAL BLOODSTEM CELLS (PBSC) WITH G-CSF ALONE, IN MULTIPLE MYELOMA(MM) PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANTATION:A PROSPECTIVE STUDY

STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: SINGLECENTER EXPERIENCE

BORTEZOMIB BASED REGIMEN IN YOUNG HIGH RISK MULTIPLEMYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELLTRANSPLANTATION: TWO CLINICAL CASES

AUTOLOGOUS STEM CELL TRANSPLANTATION AND PRIMARYSYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS

FOUR PHASE 3 STUDIES OF THE ORAL PROTEASOME INHIBITOR(PI) IXAZOMIB FORMULTIPLEMYELOMAINTHENEWLY-DIAGNOSED,RELAPSED/REFRACTORY, AND MAINTENANCE SETTINGS:TOURMALINE-MM1, -MM2, -MM3, AND -MM4

CENTAURUS (JNJ5467414SMM2001):ARANDOMIZEDPHASE II TRIALTO EVALUATE THREE DARATUMUMAB (DARA) DOSE SCHEDULESIN SMOLDERING MULTIPLE MYELOMA (SMM)

C. Cecchini

J. Radocha

H. Mrachacz

T. Dejoie

R. GarciaSanchez

H.N. Song

E. Kaul

J.R. Eveillard

R. Ríos-Tamayo

R.R. Boya

Z. Bolaman

M. Quaresima

S.K. Toprak

J. San Miguel

C.C. Hofmeister

PO-149

PO-150

PO-151

PO-152

PO-153

PO-154

PO-155

PO-156

PO-157

PO-158

PO-159

PO-160

PO-161

PO-162

PO-163

3. Epidemiology, QoL, Toxicities, and Other Plasma Cell Dyscrasias

POSTER DISCUSSION SESSIONChairman: Raymond L. Comenzo

POSTER SESSION

5554



CARDIAC AMYLOID IMAGING WITH 18F-FLORBETABEN POSITRONEMISSION TOMOGRAPHY: A PILOT STUDY

DEVELOPMENT OF MONOCLONAL GAMMOPATHY OF UNDE-TERMINED SIGNIFICANCEAFTER KIDNEY TRANSPLANT

RISK OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WITHMULTIPLE MYELOMA RECEIVING NOVEL THERAPIES: A SINGLEASIAN MEDICAL CENTER STUDY

POSSIBLE NEWDISEASE ENTITYOFALAMYLOIDOSIS INDUCED BYDEPOSITION OF IGLC2

CONTINUED IMPROVEMENT IN OVERALL SURVIVAL IN ELDERLYMULTIPLE MYELOMAPATIENTSAFTER 2008; APOPULATION BASEDSTUDY FROM THE DANISH MULTIPLE MYELOMAREGISTRY

IS THROMBOPROPHYLAXIS NECESSARY FOR MYELOMAPATIENTS? A CLINICAL DILEMMAAND PROPOSAL OF A PRACTICALGUIDELINE

VIRALRESPIRATORYTRACT INFECTION IN PATIENTSWITH PLASMACELL DISORDER IN CURRENT STANDARD TREATMENT

REAL WORLD MANAGEMENT OF MULTIPLE MYELOMA: INITIALRESULTS FROM THE AUSTRALIA AND NEW ZEALAND MYELOMAAND RELATED DISEASES REGISTRY

PATIENT POPULATION WITH MULTIPLE MYELOMA ANDTRANSITIONSACROSS LINESOFTHERAPY INTHEUNITEDSTATES:AN EPIDEMIOLOGIC MODEL

UP-REGULATIONOFTNFRSF13ANDHMGB1 INWALDENSTROMMA-CROGLOBULINEMIA WITH OSTEOLYTIC BONE LESION

HEAVY/LIGHT CHAIN IMMUNOPARESIS IDENTIFIES SYSTEMIC ALAMYLOIDOSIS PATIENTS WITH POOR SURVIVAL OUTCOMES

ADHERENCE TO ORAL IMMUNOMODULATORY THERAPY AT ACOMMUNITY CANCER CENTER

PROGNOSTIC VALUE OF HEVYLITE CHAIN IN A POPULATIONCOHORT OF MONOCLONAL GAMMOPATHY OF UNCERTAIN SI-GNIFICANCE

PREVALENCE OF THE ALTERATION OF THE RATIO KAPPA/LAMBDABY FREELITE® IN BLOODDONORSOVER FORTYYEARSOFAGEATSANTACASAOF SÃO PAULO: PRELIMINARYANALYSIS

EXPECTANCY OF LIFE AND INCIDENCE RATE OF NEWLYDIAGNOSEDMULTIPLEMYELOMA(NDMM) PATIENTS. 15 YEARSRE-TROSPECTIVEANALYSIS

CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE(CYBORD) FORTHETREATMENTOFALAMYLOIDOSIS: EXPERIENCEATASINGLE INSTITUTION

P. Mollee

J.W. Tan

P. Hsu

E. Fujii

N. Abildgaard

A. Kato

M.Y. Lee

E. Moore

J. Cid Ruzafa

N. Sekiguchi

S. Sachchitha-nantham

A. Benyounes

A. García Mateo

M.M. Arruda

B. Ballina

V.H. JimenezZepeda

PO-182

PO-183

PO-184

PO-185

PO-186

PO-188

PO-189

PO-190

PO-191

PO-192

PO-193

PO-194

PO-195

PO-196

PO-197

PO-198

THE EFFECT OF BORTEZOMIB TREATMENT ON ANTIBODY TITERSAGAINST COMMON VIRALAND VACCINEANTIGENS

CONDITIONAL SURVIVAL ANALYSIS OF MULTIPLE MYELOMAPATIENTS: EXPERIENCE OF THE COMPREHENSIVE CANCERCENTER FREIBURG (CCCF) UNIVERSITY MEDICAL CENTERFREIBURG

HEAVY CHAIN DISEASES: ARETROSPECTIVE STUDY

LESS THAN 30% OF RELAPSED LIGHT CHAIN (AL) AMYLOIDOSISPATIENTS WITH PROGRESSIVE DISEASE REQUIRING THERAPYHAVE MEASURABLE SERUM FREE LIGHT CHAIN DIFFERENCES(DFLC): BETTER CRITERIA TO DEFINE HEMATOLOGIC PRO-GRESSIONARE NEEDED

SURVIVAL ANALYSIS IN NEWLY DIAGNOSED MULTIPLE MYELOMAPATIENTS IN THE UNITED STATES MEDICARE DATABASE

CLINICAL PREVALENCE OF MONOCLONAL GAMMOPATHY OF UN-DETERMINED SIGNIFICANCE (MGUS) IN THE UNITED STATES:ESTIMATING THE BURDEN ON HEALTH CARE

CLINICAL CHARACTERISTICS, OUTCOMES AND PREDICTORS OFPROGRESSION TOMULTIPLE MYELOMA (MM) IN 61 PATIENTSWITHSOLITARY PLASMACYTOMA

VALIDATION OF THE 2012 HEMATOLOGIC RESPONSE CRITERIA INLIGHT CHAIN AMYLOIDOSIS USING THE CENTER FOR INTER-NATIONAL BLOOD AND MARROW TRANSPLANT (CIBMTR)DATABASE

THE INCIDENCEANDCLINICALFEATURESOFHBVREACTIVATION INMULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTSAND/ORASCT: ARETROSPECTIVE MULTICENTER STUDY IN JAPAN

COLD AGGLUTININ DISEASE IS A PHENOTYPICALLY DISTINCTCLONAL B-CELL DISORDER

THE PRESENCE OF MYD88 L265P IN NON-IGM LYMPHOPLA-SMACYTIC LYMPHOMA: IMPLICATIONS FOR DIAGNOSIS ANDTHERAPY

EVALUATING THE USE OF MULTIPARAMETRIC FLOW CYTOMETRYIN ESTABLISHING THE PRESENCE OFMINIMALRESIDUALDISEASEIN SYSTEMICALAMYLOIDOSIS: AREPORT OF EIGHT PATIENTS

HOSPITALIZATION RATES FOR NEWLY DIAGNOSED MULTIPLEMYELOMAPATIENTS IN THE UNITED STATESMEDICARE DATABASE

LECT2AMYLOIDOSIS: NOT JUSTAHISPANIC DISEASE

PROGRESSIVE INNOVATION IN ONCOLOGY: VALUING OUTCOMESBEYOND SURVIVAL

K. Celotto

J.M. Wal-dschmidt

C. ChapuisCellierH. Landau

A.A. Yusuf

R.S. Go

E.E. Manasanch

A. D’Souza

Y. Tsukune

R. De Tute

R. De Tute

M. Coyne

A.A. Yusuf

J. Ramzy

C. Quinn

PO-167

PO-168

PO-169

PO-170

PO-171

PO-172

PO-173

PO-174

PO-175

PO-176

PO-177

PO-178

PO-179

PO-180

PO-181

5756



PRIMARY SYSTEMIC AMYLOIDOSIS ASSOCIATED WITH MULTIPLEMYELOMA. OUR EXPERIENCE

SECOND MALIGNANCIES AND MULTIPLE MYELOMA. A SINGLE-IN-STITUTION EXPERIENCE IN SPAIN

SCLEREDEMAASSOCIATED WITH MULTIPLE MYELOMA OR MGUS:TREATMENT REPORT OF FOUR CASES

SUBCUTANEOUS BORTEZOMIB-INDUCED PARALYTIC ILEUS INMULTIPLE MYELOMAPATIENTS

DISSEMINATED CRYPTOCOCCAL INFECTION IN AN IMMUNO-COMPETENT HOST MIMICKING PLASMA CELL DISORDER: A CASEREPORTAND LITERATURE REVIEW

POMALIDOMIDE AND DEXAMETHASONE ASSOCIATION IS ANEFFECTIVE SALVAGE THERAPY IN SECONDARY PLASMA CELLLEUKAEMIA (SPCL)

THE IMPORTANCE OF FUNDUS EXAMINATION FOR FEVERETIOLOGY INAPATIENTWITH MYELOMA

CASE STUDY: AN EXAMPLE OF MANUAL PLASMA EXCHANGE IN ACHALLENGING PATIENT WITH HYPERVISCOSITY SECONDARY TOWALDENSTROM'S MACROGLOBULINAEMIA

F. Almagro Torres

S. Cerdá

M. Krejci

G. Mele

M.B. Abid

G. Mele

Z. Bolaman

N. Shanmugana-than

PO-216

PO-217

PO-218

PO-219

PO-220

PO-221

PO-222

PO-223

A RETROSPECTIVE ANALYSIS AT THE PRINCESS MARGARETCANCER CENTRE OF THE INITIAL THERAPY OF AL AMYLOIDOSIS:CYBORD VERSUS OTHER REGIMENS

TREATMENT RESULTS OF VENOUS THROMBOEMBOLISM WITHDALTEPARIN IN PATIENTSWITHMULTIPLEMYELOMAUNDERGOINGANTI-MYELOMACHEMOTHERAPEUTICAGENTS

SUBCUTANEOUS IMMUNOGLOBULIN FOR TREATMENT OFSECONDARY HYPOGAMMAGLOBULINEMIA IN MULTIPLE MYELOMA

POEMS SYNDROME: A RETROSPECTIVE ANALYSIS OF CLINICOPA-THOLOGICAL PROFILE AND TREATMENT OUTCOMES OF 43 CON-SECUTIVE CASES FROMATERTIARY CANCER CENTRE IN INDIA

FOLLOWING THE GUIDELINES FOR REDUCING OSTEONECROSISOF THE JAW ASSOCIATED WITH BISPHOSPHONATE THERAPY INSYMPTOMATIC MULTIPLE MYELOMA - EXPERIENCE OFADISTRICTGENERAL HOSPITAL

SECONDARYMALIGNANCIES IN MULTIPLE MYELOMA

AUTOLOGOUS HCT IN ELDERLY MYELOMA PATIENTS, AHNCISINGLE INSTITUTION EXPERIENCE

BLEEDING DIATHESIS AND PROTHROMBOTIC TENDENCIES INPATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LIGHT CHAINAMY-LOIDOSIS: IMPORTANT CLINICAL IMPLICATIONS

CZECH MYELOMA GROUP REGISTRY OF MONOCLONAL GAM-MOPATHIES

PLASMACELL LEUKEMIA. EXPERIENCE IN OUR CENTER

QUALITY OF LIFE IN MULTIPLE MYELOMA: VALIDATION OF THETURKISH VERSION OF THE QLQ-MY20 INSTRUMENT

THE VERIFICATION OF RENAL PROGNOSIS OFALAMYLOIDOSIS

FINDING THE MEANING OF LIFE OF PATIENTS WITH MULTIPLEMYELOMA CORRELATES WITH BETTER CONTROL OF THEIRDISEASE BY CHEMOTHERAPY

INCIDENCE OF NEUROPATHY IN PATIENTS TREATED WITHBORTEZOMIB SUBCUTANEOUS

MONOCLONALGAMMOPATHYOFRENALSIGNIFICANCE (MGRS).HE-MATOLOGICAL AND RENAL COMPLETE RESPONSE WITHBORTEZOMIB

SAFETY AND ADHESION WITH SUBCUTANEOUS BORTEZOMIBTREATMENT IN MULTIPLE MYELOMA

INCIDENCE OF PERIPHERAL NEUROPATHY IN CLINICAL PRACTICEIN MULTIPLE MYELOMAPATIENTS TREATEDWITH REGIMENSWITHSUBCUTANEOUSADMINISTRATION OF BORTEZOMIB

R. Kaedbey

C.K. Min

R. Ria

R. Pramanik

J. Page

C. Vadikoliou

E. Sahovic

S. Mahmood

V. Maisnar

F. Almagro Torres

O.G. Sevindik

Y. Yoshiki

P.P. Kotoucek

A. VicentCastelló

A. Alegre

F. Escalante

A. Garcia-Guiñon

PO-199

PO-200

PO-201

PO-202

PO-203

PO-204

PO-205

PO-206

PO-207

PO-208

PO-209

PO-210

PO-211

PO-212

PO-213

PO-214

PO-215

5958



TARGETING HEPARANASE TO INHIBIT MYELOMA CHEMORE-SISTANCE

EZH2 OVEREXPRESSION IN MYELOMA PATIENTS SHORTENSSURVIVALAND IN-VITRO DATASUPPORTSAPOTENTIAL NEWTARGETED TREATMENT STRATEGY

FILANESIB (ARRY-520) DEMONSTRATES POTENT AND RAPIDACTIVITY IN PRECLINICAL MODELS OF MM, DEPENDENT ON BCL-2FAMILY EXPRESSION, AND SYNERGISTIC WITH DEXAMETHASONEAND IMIDS

REVERSE SIGNALING VIA B7-H1/PD-1 INTERACTION AND CLINICALCHARACTERISTICS OF B7-H1 (PD-L1) EXPRESSED ON MULTIPLEMYELOMACELLS

INHIBITION OF H3K9 METHYLTRANSFERASE AS A POTENT THE-RAPEUTIC TARGET IN MULTIPLE MYELOMA

THE AP-1 TRANSCRIPTION FACTOR JUNB PROMOTES MULTIPLEMYELOMA (MM) CELL PROLIFERATION, SURVIVAL AND DRUG RE-SISTANCE IN THE BONE MARROWMICROENVIRONMENT

A NOVEL FUNCTION OF DEPTOR IN MULTIPLE MYELOMA:COMMITMENT TO PLASMACELLMATURATION

MIR-137 CONTRIBUTES TO DRUG SUSCEPTIBILITY ANDCHROMOSOMAL INSTABILITY OF MULTIPLE MYELOMA THROUGHTARGETINGAURKA

SURGICAL CONTROL/CURE OF 5TGM1 MURINE MULTIPLEMYELOMAMODEL BY THYROPARATHYROIDECTOMY

MMSET I ACTS AS AN ONCOGENE IN T(4;14) MULTIPLE MYELOMACELLS

EFFECTIVE IMPAIRMENT OF MYELOMA PROGENITORS BY HY-PERTHERMIA: AUGMENTATION WITH BORTEZOMIB AND PIM IN-HIBITION IN COMBINATION

PRECLINICALANTIMYELOMAACTIVITY OF EDO-S101

BONE MARROW ANGIOGENIC POTENTIAL AND MOLECULAR EX-PRESSION OF CELL-CELL ADHESION MOLECULES AND MATRIX-METALLO PROTEINASES IN MULTIPLE MYELOMA

CANCER-TESTIS ANTIGEN SLLP1 REPRESENTS A PROMISINGTARGET FOR THE IMMUNOTHERAPY OF MULTIPLE MYELOMA

PRL-3 INCREASES SURVIVAL OF MULTIPLE MYELOMA CELLSTHROUGH SRCACTIVATION

A NOVEL HUMAN FC-OPTIMIZED ICAM-1/CD54 ANTIBODY (MSH-TP15E) WITH POTENT ANTI-MYELOMA ACTIVITY IN VITRO AND INVIVO

V.C. Ramani

C. Pawlyn

S. Hernández-García

M. Ishibashi

J. Devin

F. Fan

D. Quwaider

Y. Qin

M. Zangari

Z. Xie

H. Miki

A.A. López-IglesiasM.C. Rapanotti

S. Yousef

P. Abdollahi

K. Klausz

PO-227

PO-228

PO-229

PO-230

PO-231

PO-232

PO-233

PO-234

PO-235

PO-236

PO-237

PO-238

PO-239

PO-240

PO-241

PO-242

FUNCTIONAL MAPPING OF MULTIPLE MYELOMA KINOME WITHLIBRARY OF SMALLMOLECULE INHIBITORS

IDENTIFICATION OF FAM46C AS A TUMOR SUPPRESSOR INMULTIPLE MYELOMA

TARGETING MYC VIAARK5 IN MULTIPLE MYELOMA

ADOPTIVE B-CELL TRANSFER MOUSE MODEL OF HUMANMYELOMA

CYTOTOXIC CD8+ T CELLS IN MYELOMA ARE IN A STATE OFTELOMERE-INDEPENDENT SENESCENCE RATHER THAN ANEXHAUSTED OR ANERGIC STATE: IMPLICATION FOR IMMUNECHECKPOINT BLOCKADE

ANTI-MYELOMA ACTIVITY OF CS-1-SPECIFIC CHIMERIC ANTIGENRECEPTOR (CAR) EXPRESSING T CELLS IN VITRO AND IN PRE-CLINICAL IN VIVO MODELS

ROLE OF RECQ1 HELICASE IN MULTIPLE MYELOMA DRUG RE-SISTANCE

A PLASTIC SQSTM1/P62-DEPENDENT AUTOPHAGIC RESERVEMAINTAINS PROTEIN HOMEOSTASIS AND DETERMINESPROTEASOME INHIBITOR SUSCEPTIBILITY IN MULTIPLE MYELOMACELLS

TOP2A KNOCKDOWN RESENSITIZES CARFILZOMIB-RESISTANTHMCLS TO CARFILZOMIB

IMIDS INDUCED IKAROS-DEPENDENT DOWNREGULATION OF MYCIN MYELOMA IS MEDIATED THROUGH THE REPRESSION OF THE 3’IGH ENHANCER ACTIVITY AND THE NURD COMPLEX REPO-SITIONING

GRANULOCYTE-LIKE MYELOID DERIVED SUPPRESSOR CELLS (G-MDSCS) ARE INCREASED IN MULTIPLE MYELOMA DUE TO IMMU-NOLOGICAL DYSREGULATION OF MESENCHYMAL STEM CELLS(MSCS)

TARGETING THE WNT CANONICAL PATHWAY IN MULTIPLEMYELOMA (MM) WITH BC2059, A NEW ORALLY BIOAVAILABLE Β-CATENIN INHIBITOR

TRAMETINIB COMBINED WITH DEXAMETHASONE INDUCES BIM-DEPENDENT SYNERGISTIC KILLING OF PREVIOUSLY DEXA-METHASONE-REFRACTORY MYELOMA

E. Dhimolea

Y.X. Zhu

S. Parekh

S. Janz

H. Suen

T. Gogishvili

E. Viziteu

T. Perini

A. Reale

P. Neri

C. Giallongo

I. Savvidou

T. Khong

BP-031

BP-032

BP-033

BP-034

BP-035

BP-036

BP-037

BP-038

BP-039

BP-040

PO-224

PO-225

PO-226

4. Multiple Myeloma Biology, Pathophysiology, Preclinical Studies, Bone Disease

POSTER DISCUSSION SESSIONChairman: Noopur Raye

POSTER SESSION

6160



TARGETING OF BMI-1 BY THE SMALL MOLECULE INHIBITOR PTC-209 DEMONSTRATES POTENTANTI-MYELOMAACTIVITY IN VITRO

GDF15 PROMOTES OSTEOCLAST DIFFERENTIATION AND HIGHSERUM GDF15 LEVELS ARE ASSOCIATED WITH MULTIPLEMYELOMABONE DISEASE

TARGETING METABOLISM IN MULTIPLE MYELOMA ENHANCES BIMBINDING TO BCL-2 ELICITING SYNTHETIC LETHALITY TOABT-199

GRP78 (78-KDAGLUCOSE-REGULATEDPROTEIN) ISAPOTENTIALLYUSEFUL BIOMARKER FOR PREDICTING RESPONSEAND SURVIVALOUTCOME IN PATIENTS WITH MULTIPLE MYELOMA, AND IS A PO-TENTIALLY USEFUL TARGET IN THE TREATMENT OF MULTIPLEMYELOMA

BORTEZOMIB-ANDCARFILZOMIB-RESISTANTMULTIPLEMYELOMACELLSGENERATED IN VITROMATCHTHEMOLECULARHALLMARKSOF BORTEZOMIB-RESISTANT PRIMARY MYELOMA CELLS, BUTDIFFER INTHEIR SENSITIVITYTO BORTEZOMIB, CARFILZOMIBANDNOVEL PROTEASOME INHIBITING DRUGS

L-PLASTIN FUNCTION IN DRUGRESISTANCEAND IMMUNESYSTEMRESISTANCE

NOTCH SIGNALING DYSREGULATION PROMOTES MULTIPLEMYELOMA-ASSOCIATED BONE DISEASE

NOTCH PATHWAY AND INTELEUKIN-6 COOPERATE TO SUPPORTMULTIPLE MYELOMACELL PROLIFERATION

FOXM1 IS A THERAPEUTIC TARGET IN HIGH-RISK MULTIPLEMYELOMA

STK405759 ASANOVELDRUG FORMULTIPLE MYELOMATHERAPY

FREQUENCY OF PROTEASE ACTIVATED RECEPTOR1 (PAR1) EX-PRESSION AND THE IN VITRO EFFECTS OF XT5 AND XT2B, TWONOVELPAR1BINDINGMOLECULES, ONPRIMARYANDBORTEZOMIBREFRACTORYMYELOMACELL LINES

CO-INHIBITORY MOLECULE VSIG4 NEGATIVELY REGULATESHELPER T CELL-DEPENDENT ISOTYPE SWITCHINGANDANTIBODYRESPONSE

BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND BONE RE-SORPTION THROUGH MODULATION OF CHIT1 AND YKL40 EX-PRESSION

SURVIVIN SUPPRESSANT YM155 INDUCES CELL DEATH VIA PRO-TEASOMAL DEGRADATION OF C-MYC IN MULTIPLE MYELOMACELLS

CD229 IS EXPRESSED ON THE SURFACE OF PLASMA CELLSCARRYING AN ABERRANT PHENOTYPE AND CHEMOTHERAPY-RESISTANT PRECURSOR CELLS IN MULTIPLE MYELOMA

A. Bolomsky

M. Westrin

R. Bajpai

H. Quach

L. Besse

N. Aouali

S. Garavelli

S. Galletti

C. Gu

G. Rozic

M. Beksac

K. Jung

D. Tibullo

M. Asahi

S. Yousef

PO-259

PO-260

PO-261

PO-262

PO-263

PO-264

PO-265

PO-266

PO-267

PO-268

PO-269

PO-270

PO-271

PO-272

PO-273

IDENTIFICATION OF FAM46CASATUMOR SUPPRESSOR INMULTIPLE MYELOMA

THENOVELPAN-PIM KINASE INHIBITOR, LGH447, SHOWSDUALAN-TITUMORAL AND BONE ANTIRESORPTIVE EFFECT IN MULTIPLEMYELOMA AND SYNERGIZES WITH STANDARD-OF-CARETREATMENTS

HISTONE DEACETYLASE 11 (HDAC11) IS CRITICAL FOR PLASMACELL DEVELOPMENTAND MULTIPLE MYELOMASURVIVAL

MULTIPLE MYELOMA (MM) PATIENTS IN LONG TERM COMPLETEREMISSION (LTCR) AFTER AUTOLOGUS TRANSPLANTATIONEXPRESSADISTINCTIVE INMUNE “FOOTPRINT”. ASINGLE CENTREEXPERIENCE

HIGH LEVELS OF PERIOSTIN IN PATIENTS WITH MULTIPLEMYELOMACORRELATEWITH LOW BONE FORMATION, INCREASEDFRACTURE RATEAND DIFFUSE MRI PATTERN

A NOVEL 3D HIGH-THROUGHPUT COCULTURE PLATFORM FORMULTIPLE MYELOMA EX-VIVO SENSITIVITY TESTING AND DRUGSCREENING

MULTIPLEMYELOMADRUGRESISTANCE:ALLROADS LEADTOKLF9

OSTEOPROTEGERIN ISASIGNIFICANT PROGNOSTIC FACTOR FOROVERALL SURVIVAL IN PATIENTS WITH PRIMARY SYSTEMIC AMY-LOIDOSIS INDEPENDENT OF THE MAYO STAGING

THE KCA2.3 POTASSIUM CHANNEL AT 1Q21 IS ASSOCIATED WITHDISEASE PROGRESSION AND REDUCED SURVIVAL DURINGRELAPSE IN MULTIPLE MYELOMA

IN VIVO FLUORESCENT IMAGINGOFMULTIPLEMYELOMA IN TRAN-SPARENTIZING XENOGRAFT MODEL

CHARACTERIZATION OF TCR REPERTOIRE OF CD4+ AND CD8+ TCELLS FROM PATIENTS WITH MULTIPLE MYELOMA IN SUSTAINEDCOMPLETE REMISSION

RASSF4 FUNCTIONS AS A TUMOR SUPPRESSOR IN MULTIPLEMYELOMA

NOTCH SIGNALING DRIVES MYELOMA CELLS HOMING TO THEBONE MARROW BY REGULATING THE CXCR4/CXCL12 AXIS

IDENTIFYINGDISEASEPROGRESSIONEVENTS INMULTIPLEMYELOMA

SCLEROSTIN REMAINS ELEVATED EVEN IN THE PLATEAU PHASEOF MYELOMA PATIENTS: IMPLICATIONS INTO THE PATHOGENESISOF OSTEOBLAST DYSFUNCTION OF MULTIPLE MYELOMA

BETBROMODOMAIN BLOCKADEENHANCES IKAROS INHIBITIONBYLENALIDOMIDE THERAPY PROVIDING ADDITIONAL ACTIVITY IN INVITROAND IN VIVO MODELS OF MULTIPLE MYELOMA

Y.X. Zhu

T. Paíno

J. Brayer

A. Arteche

E. Terpos

J.M. Wal-dschmidt

M. Nikiforov

E. Kastritis

H.M. Nurul

Y. Mishima

E. Lozano

E. De Smedt

M. Colombo

A. Brown

E. Terpos

T. Diaz

PO-243

PO-244

PO-245

PO-246

PO-247

PO-248

PO-249

PO-250

PO-251

PO-252

PO-253

PO-254

PO-255

PO-256

PO-257

PO-258

6362



CHARACTERIZATION OF HEAT SHOCK FACTOR 1 IN RESPONSE TOPROTEASOME INHIBITION UNVEILS A NOVEL THERAPEUTICSTRATEGY FOR MULTIPLE MYELOMATREATMENT

BUFALIN INDUCESAPOPTOSIS INMYELOMACELLS THROUGHDNADAMAGEAT HYPOXIC CONDITIONS

AUTOLOGOUSACTIVATEDANDEXPANDEDNATURALKILLERCELLSDESTROY MULTIPLE MYELOMA CLONOGENIC TUMOR CELLSTHROUGH NKG2DAND ITS LIGANDS

CLINICOPATHOLOGICAL ANALYSIS OF MULTIPLE MYELOMA WITHCENTRAL NERVOUS SYSTEM INVOLVEMENT

LENALIDOMIDE INCREASESHUMANDENDRITIC CELLMATURATIONMODULATING BOTH MONOCYTE DIFFERENTIATION AND ME-SENCHYMAL STROMALCELL INHIBITORY PROPERTIES BY IKAROSDEPENDENTAND INDEPENDENT MECHANISMS

COMPARISON OF POLYCLONAL AND MONOCLONAL ANTIBODYBASED FREE LIGHT CHAIN ASSAYS TAKING ACCOUNT OF RENALFUNCTION

STRUCTURAL CHARACTERISATION OF IMMUNOGLOBULIN G GLY-COSYLATION IN MULTIPLE MYELOMA

C-METASSOCIATEDWITH OSTEOGENESIS IN MULTIPLE MYELOMAPATIENTS BY INDUCTIONOFMMP9 EXPRESSIONBYHGF IN BMSCS

EXPRESSION OF CANCER TESTIS ANTIGENS (CTAS) IN PLA-SMACYTOMAWITHANDWITHOUT BONE MARROW INVOLVEMENT

INCREASED DNP73 PROMOTES MYELOMA CELL GROWTH ANDREPRESSES DNADAMAGE-INDUCEDAPOPTOSIS

CLONAL EVOLUTIONAL PATHS IN MULTIPLE MYELOMA REVEALEDIN SINGLE CELL OF SEQUENTIAL ANALYSIS AND ITS CLINICAL SI-GNIFICANCE

IMPACTOF LENALIDOMIDEANDDEXAMETHASONETREATMENTONIMMUNE CELL POPULATIONS OF THE PATIENTS WITH RE-FRACTORY/RELAPSED MULTIPLE MYELOMA

TARGETAND RESISTANCE RELATED PROTEINS OF RECOMBINATEMUTANTHUMANTUMORNECROSIS FACTOR-RELATEDAPOPTOSIS-INDUCING LIGAND (RMHTRAIL) ON MYELOMACELL LINES

AMILORIDE INDUCESPOTENTANTITUMORALACTIVITY INMULTIPLEMYELOMATHROUGH THE REACTIVATION OF MUTANT P53

CDC37 SUPPRESSING IN MULTIPLE MYELOMA BLOCKS PROLI-FERATION BUT INDUCES BORTEZOMIB RESISTANCE

SERUMCYTOKINE LEVELS IN PATIENTSOFMULTIPLEMYELOMAATDIAGNOSIS ANDAT RELAPSE

S. Shah

E. Fujii

A. Leivas

S. Morita

F. Costa

O. Decaux

G.N. Le

H. Park

A. Jungbluth

M. Hao

X. Qin

C.K. Min

Y. Jian

E. Rojas

M. Zang

S. Jasrotia

PO-289

PO-290

PO-291

PO-292

PO-293

PO-294

PO-295

PO-296

PO-297

PO-298

PO-299

PO-300

PO-301

PO-302

PO-303

PO-304

THECHEMOKINECXCL9 (MIG) ISAN INDEPENDENTPREDICTOROFOVERALL SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA

N-CADHERIN IS A THERAPEUTIC TARGET IN T(4;14)-POSITIVEMULTIPLE MYELOMA

MYELOMA-DERIVED CCL27 INDUCES STROMA-DEPENDENT RE-SISTANCEAGAINST BORTEZOMIB VIAUPREGULATION OF IL-10

POTENTIAL ROLE OF EXOSOME-ASSOCIATED MICRORNA PANELSAND IN VIVO ENVIRONMENT TO PREDICT DRUG RESISTANCE FORPATIENTS WITH MULTIPLE MYELOMA IN THE ERA OF NOVELAGENTS: A RETROSPECTIVE ANALYSIS OF REAL-WORLD DATAFROMACHINESE CENTER OF HEMATOLOGICAL DISEASE

INVOLVEMENT OF NOTCH SIGNALING IN MULTIPLE MYELOMAAN-GIOGENESIS AND PROGRESSION

INHIBITIONOFMTORASANTIANGIOGENIC STRATEGY INMULTIPLEMYELOMA

CORRELATIONOFTHEPARAMETERSOFMYELOMABONEDISEASESIGNALLINGTOTHEACTIVITYOFMULTIPLEMYELOMAANDTOTHERISK OF TRANSFORMATION IN MONOCLONAL GAMMOPATHY OFUNDETERMINED SIGNIFICANCE

ROLE OF NUCLEAR HEME OXYGENASE 1 (HO-1) IN BORTEZOMIBINDUCED CELL DEATH AND GENOMIC INSTABILITY OF MULTIPLEMYELOMA (MM) CELLS

HUWE1 IS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLEMYELOMA

EXPRESSIONAND FUNCTIONOFSLAMFAMILYMOLECULE SLAMF3(CD229) IN MYELOMA

DEFICIENCY IN DNA REPAIR PATHWAYS OF PERIPHERAL BLOODMONONUCLEAR CELLS CORRELATES WITH BETTER CLINICALOUTCOME OF MYELOMAPATIENTS

ALTERATION OF PIM-2 EXPRESSION BY CLINICALLY AVAILABLEANTI-MYELOMAAGENTS: COMBINATORYANTI-MYELOMAEFFECTSWITH PIM INHIBITION

RELATION BETWEEN LYMPHOCYTES AND DENDRITIC CELLS - IM-PLICATIONS FORTHE EFFECTIVENESSOFAN IMMUNE RESPONSETO NEOPLASTIC ANTIGENS IN PATIENTS SUFFERING FROMMULTIPLE MYELOMA

THE MECHANISMS AND EFFECTS OF LONG NONCODING RNAMA-TERNALLY EXPRESSED 3 IN MULTIPLE MYELOMA

THE CURRENT UNMET MEDICAL NEEDS IN THE TREATMENT ANDMANAGEMENT OF MULTIPLE MYELOMA (MM)

A. Bolomsky

K.M. Mrozik

S. Thangavadivel

L. Zhang

I. Saltarella

A. Lamanuzzi

J. Minarik

D. Tibullo

L.J. Crawford

A. Yamada

M. Gkotzamanidou

N. Shingen

E. Grywalska

X. Qu

P.G. Richardson

PO-274

PO-275

PO-276

PO-277

PO-278

PO-279

PO-280

PO-281

PO-282

PO-283

PO-284

PO-285

PO-286

PO-287

PO-288

6564



LENALIDOMIDE-DEXAMETHASONE OR MELPHALAN-LENALIDO-MIDE-PREDNISONE (MPR)ORCYCLOPHOSPHAMIDE-PREDNISONE-LENALIDOMIDE (CPR) FOR INITIAL TREATMENT OF REAL LIFEELDERLYPATIENTSWITHNEWLYDIAGNOSEDMULTIPLEMYELOMA

AGE VERSUS FRAILTY. WHAT SHOULD DETERMINE TREATMENTCHOICE IN THE ELDERLY MYELOMAPATIENTS THESE DAYS?

WEEKLY CARFILZOMIB IN COMBINATION WITH CYCLOPHOSPHA-MIDE AND DEXAMETHASONE (WCCYD) IN PATIENTS (PTS) WITHNEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): A PHASE 1/2STUDYOF THE EUROPEANMYELOMANETWORK TRIALIST GROUP

BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BBD) ASFIRST-LINE TREATMENT OF PATIENTS (PTS) WITH MULTIPLE MYE-LOMA (MM) WHO ARE NOT CANDIDATES FOR HIGH DOSE CHEMO-THERAPY

9-YEAR FOLLOW-UP BORTEZOMIB, THALIDOMIDE, DEXAMETHA-SONE INDUCTION THERAPY FOLLOWED BY MELPHALAN, PREDNI-SOLONE, THALIDOMIDECONSOLIDATIONTHERAPYASAFIRSTLINEOF TREATMENT FOR PATIENTS WITH MULTIPLE MYELOMA WHOARE NON-TRANSPLANT CANDIDATES: RESULTS OF THE KOREANMULTIPLE MYELOMAWORKING PARTY (KMMWP)

RANDOMIZEDPHASE II TRIALOFCOMBINATION IDIOTYPEVACCINEAND ANTI-CD3/ANTI-CD28 COSTIMULATED AUTOLOGOUS T CELLSIN PATIENTS WITH MULTIPLE MYELOMA POST-AUTOTRANSPLAN-TATION

ARANDOMIZED PHASE III TRIAL OF BUSULFAN + MELPHALAN (BU-MEL) VS MELPHALAN ALONE FOR MULTIPLE MYELOMA: LONGERPFS IN THE BU-MELARM

MATCHED-PAIRS ANALYSIS OF OUTCOMES WITH BORTEZOMIB,MELPHALAN,AND PREDNISONE (VMP) TREATMENT FOR PREVIOU-SLY UNTREATED MULTIPLE MYELOMA (MM) USING LONG-TERMFOLLOW-UPDATAFROMTHEPHASE 3 VISTAANDPETHEMA/GEM05TRIALS

CLINICAL IMPACT OF DEPTH OF RESPONSE ON 3 MONTHS AFTERSTARTING CHEMOTHERAPY AND CUMULATIVE DOSE OF BORTE-ZOMIB ON SURVIVAL IN ELDERLY PATIENTS WITH MULTIPLE MYE-LOMA WHO TREATED WITH BORTEZOMIB COMBINED MELPHALANPLUS PREDNISOLONE ; HOW TO IMPROVE SURVIVAL RATES BYLONGER DURATION OF TREATMENT AND EARLY DEEPER RE-SPONSE

HIGH VERSUS ATTENUATED DOSE DEXAMETHASONE HAS LITTLEEFFECT ON THE SPEED OR DEPTH OF RESPONSE TO INDUCTIONTHERAPY FOR MYELOMA

V. Magarotto

S.G.R. Verelst

S. Bringhen

J.G. Berdeja

E. Lee

M.H. Qazilbash

M.H. Qazilbash

M.V. Mateos

H.S. Lee

H. Giles

BP-041

BP-042

BP-043

BP-044

BP-045

BP-046

BP-047

BP-048

BP-049

BP-050

A NOVEL SMALL MOLECULE COMPOUND DISPLAYS PRECLINICALACTIVITYAGAINSTMULTIPLEMYELOMABYDISRUPTINGTHEMTORSIGNALING PATHWAY

THE RELATIONSHIP OF MYELOMA BONE DISEASE SIGNALLING TOTHE PARAMETERS OF BONE METABOLISM IN MONOCLONAL GAM-MOPATHIES

MYELOMA IS ASSOCIATED WITH FEATURES OF METABOLICSYNDROME

NEW TARGETED DRUGS IN MULTIPLE MYELOMA THERAPY - INVITRO STUDIES

THE RELATIONSHIP OF THE PARAMETERS OF MYELOMA BONEDISEASE SIGNALLING PATHWAYS TO THE EXTENT OF BONE IN-VOLVEMENT AND EXTRAMEDULLARY DISEASE IN MONOCLONALGAMMOPATHIES

USE OF PROTEIN-TO-CREATININE RATIO IN SPOT URINE SAMPLESFOR THE EVALUATION OF PROTEINURIA IN PATIENTS WITHMULTIPLE MYELOMA

IMMUNE AND HORMONAL PECULIARITIES AND GENDER RELATEDCHANGES IN MULTIPLE MYELOMAPATIENTS

CLINICAL SIGNIFICANCE OF GRANULES IN CYTOPLASM OF NEWLYDIAGNOSED MYELOMACELLS

K. Han

J. Minarik

M.J. Streetly

C. Geraldes

J. Minarik

E. Le Mouel

H.M.M. Ali

K. Suzuki

PO-305

PO-306

PO-307

PO-308

PO-309

PO-310

PO-311

PO-312

5. Multiple MyelomaTherapy in Newly Diagnosed Patients excluding Transplantation

POSTER DISCUSSION SESSIONChairman: Heinz Ludwig

6766



EFFICACYANDSAFETYOFCARFILZOMIB, LENALIDOMIDE,ANDDE-XAMETHASONE (KRD) VS LENALIDOMIDE AND DEXAMETHASONE(RD) IN PATIENTS (PTS) WITH RELAPSED MULTIPLE MYELOMA(RMM) BASEDONAGE: SECONDARYANALYSIS FROMTHEPHASE 3STUDYASPIRE (NCT01080391)

SUPERIORHEALTH-RELATEDQUALITYOF LIFEWITHCARFILZOMIB,LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDEAND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLEMYELOMA (MM): RESULTS FROM THEASPIRE TRIAL

STRATUS™ (MM-010): A SINGLE-ARM, PHASE 3B STUDY EVALUA-TING SAFETY AND EFFICACY OF POMALIDOMIDE (POM) +LOW-DOSEDEXAMETHASONE (LODEX) IN PATIENTS (PTS)WITHRE-FRACTORYORRELAPSEDANDREFRACTORYMULTIPLEMYELOMA(RRMM)

SURVIVAL OUTCOMES IN PATIENTS (PTS) WITH REFRACTORY ORRELAPSEDANDREFRACTORYMULTIPLEMYELOMA(RRMM) IN THEMM-003 TRIAL: IMPACT OF STABLE DISEASE (SD) AS A RESPONSETO POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (POM +LODEX)

SUBGROUP ANALYSIS BY PRIOR TREATMENT OF THE EFFICACYAND SAFETY OF PANOBINOSTAT PLUS BORTEZOMIB AND DEXA-METHASONE IN PATIENTSWITHRELAPSEDORRELAPSEDANDRE-FRACTORY MULTIPLE MYELOMA IN THE PANORAMA1 STUDY

SAFETY PROFILE OF ORAL IXAZOMIB: EXPERIENCE FROM 761 PA-TIENTS (PTS) ACROSS 14 PHASE 1 OR PHASE 1/2 CLINICAL STU-DIES

EXPOSURE-RESPONSE RELATIONSHIP OF DARATUMUMAB EFFI-CACYANDSAFETY IN PATIENTSWITHRELAPSEDORREFRACTORYMULTIPLEMYELOMA(MM)AFTERPRIORPROTEASOME INHIBITORS(PIS) AND IMMUNOMODULATORY DRUGS (IMIDS)

A PHASE I/IIA STUDY OF THE HUMAN CD38 ANTIBODY MOR202(MOR03087) IN RELAPSED OR REFRACTORYMULTIPLE MYELOMA

IBRUTINIB IN COMBINATIONWITH LOW-DOSEDEXAMETHASONE INPATIENTSWITHRELAPSEDORRELAPSEDANDREFRACTORYMUL-TIPLE MYELOMA: RESULTS FROMAMULTICENTER PHASE 2 TRIAL

PHASE I INTERIM SAFETY AND EFFICACY OF VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPYFORRELAPSED/REFRACTORY (R/R)MULTIPLE MYELOMA (MM)

A. Palumbo

A.K. Stewart

M.A. Dimopoulos

P. Moreau

P.G. Richardson

S. Lonial

X.S. Xu

M.S. Raab

P.G. Richardson

S. Kumar

BP-051

BP-052

BP-053

BP-054

BP-055

BP-056

BP-057

BP-058

BP-059

BP-060

TREATMENT OF RENAL FAILURE IN PATIENTS WITH NEWLY DIA-GNOSED MULTIPLE MIELOMA WITH BORTEZOMIB AND DEXAME-THASONE: RESULTS OF A PHASE II TRIAL FROM PETHEMA/GEMGROUP (RENVEL)

RAPID REDUCTION IN IFLC PREDICTS ACHIEVEMENT OF VGPRAFTER 4 CYCLES OF VCD TREATMENT: SHIMOUSA MM-01 VCDSTUDY

LENALIDOMIDE DOSE MODIFICATIONS AND ASSOCIATED PATIENTOUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

INTENTION TO TREAT VS AGE OF DIAGNOSIS. ANALYSIS OF BENE-FITIAL EFFECTOFNEWAGENTS INTHETREATMENTOFNEWLYDIA-GNOSED MULTIPLE MYELOMA (NDMM)

PATTERNS OF GROWTH FACTOR COSTS IN MULTIPLE MYELOMAPATIENTS TREATEDWITH LENALIDOMIDE OR BORTEZOMIB

CYCLOPHOSPHAMIDE, BORTEZOMIB AND DEXAMETHASONE (CY-BORD) FOR THE UPFRONT THERAPY OF TRANSPLANT INELIGIBLEPATIENTS WITH MULTIPLE MYELOMA

SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA IN FIRST-LINETREATMENT: THALIDOMIDE, DEXAMETHASONE AND ZOLEDRONICACID. REPORT OF THE NATIONAL CANCER INSTITUTE OF MÉXICO(INCAN)

INCIDENCE AND CHARACTERISTICS OF BACTERIAL INFECTIONSDURING INDUCTION THERAPY IN PATIENTS WITH MULTIPLE MYE-LOMATREATEDWITHNEWDRUGS.ASTUDYOF 67 PATIENTS FROMASINGLE INSTITUTION

CYBORD DEMONSTRATED ITS SUPERIORITY TO BORTEZOMIBPLUSDEXAMETHASONE INTRANSPLANT-ELIGIBLE PATIENTSWITHNEWLY DIAGNOSED MULTIPLE MYELOMA

OUTCOMES BETWEEN FRONTLINE AND SALVAGE BORTEZOMIB-BASED REGIMENS IN ELDERLY PATIENTS WITH MULTIPLE MYE-LOMA

RESULTS OF THE PROTOCOL VCD FOR MULTIPLE MYELOMA IN ASINGLE CENTER INALGERIA

IMPROVED OUTCOME BY EARLY DOSE REDUCTION AND SCHE-DULEADJUSTMENTWITH SUBCUTANEOUS INJECTION OF BORTE-ZOMIB IN ELDERLY MYELOMA PATIENTS RECEIVINGBORTEZOMIB-MELPHALAN-PREDNISONE REGIMEN

L. Rosiñol

M. Takeuchi

S. Usmani

V. MartínezRobles

S.R. Arikian

C.P. Venner

J.R. EspinozaZamora

M.F. MartínezGarcia

Y. Kusano

S.K. Sohn

M.T. Abad

H.J. Shin

PO-313

PO-314

PO-315

PO-316

PO-317

PO-318

PO-319

PO-320

PO-321

PO-322

PO-323

PO-324

6. Multiple Myeloma Therapy Relapsed/Refractory Patients

POSTER DISCUSSION SESSIONChairman: Torben Plesner

POSTER SESSION

6968



0052) PLUS LOWDOSEDEXAMETHASONE (DEX) IN PATIENTSWITHRELAPSED AND REFRACTORY MULTIPLE MYELOMA; STUDY NPI-0052-101 (NCT00461045)

PHASE 1B INTERIM RESULTS: VENETOCLAX (ABT-199/GDC-0199) INCOMBINATION WITH BORTEZOMIB (BTZ) AND DEXAMETHASONE(DEX) IN RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM)

OPROZOMIB (OPZ)ANDDEXAMETHASONE (DEX) IN PATIENTS (PTS)WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA(RRMM): UPDATED RESULTS FROM A PHASE 1B/2, MULTICENTER,OPEN-LABEL STUDY

OUTCOME OF FIRST SALVAGE THERAPY FORMULTIPLE MYELOMA(MM) IN REAL-WORLD CLINICAL PRACTICE: RESULTS FROM THETHIRD INTERIM ANALYSIS OF THE MULTINATIONAL, OBSERVATIO-NAL, NON-INTERVENTIONAL EMMOS STUDY

THE BRUTON’S TYROSINE KINASE INHIBITOR IBRUTINIB IN COMBI-NATION WITH CARFILZOMIB IN PATIENTS WITH RELAPSED OR RE-LAPSEDANDREFRACTORYMULTIPLEMYELOMA: INITIALRESULTSFROMAMULTICENTER PHASE 1/2B STUDY

VORINOSTAT (V), BORTEZOMIB (B), DOXORUBICIN (DOX) AND DE-XAMETHASONE (DEX, VBDD) IN RELAPSEDORREFRACTORYMUL-TIPLE MYELOMA PATIENTS (PTS): RESULTS OF AN OPEN,NON-COMPARATIVE, PHASE I/II INVESTIGATOR INITIATEDTRIAL (IIT)

OUTCOMEOFTREATMENTFOR FIRSTVERSUS LATERRELAPSE INMULTIPLE MYELOMA (MM) IN REAL-WORLD CLINICAL PRACTICE:RESULTS FROM THE THIRD INTERIM ANALYSIS OF THE MULTINA-TIONAL, NON-INTERVENTIONAL, OBSERVATIONAL EMMOS STUDY

OPTIMALSEQUENTIALTHERAPY IN FIRSTLINEANDFIRSTRELAPSEOF MM: APOST-HOCANALYSIS

PATTERNS OF RELAPSE AND OUTCOME OF ELDERLY MULTIPLEMYELOMA PATIENTS TREATED WITH VMP OR VTP AS INDUCTIONFOLLOWED BY MAINTENANCE WITH VT OR VP IN THE SPANISHGEM2005MAS65 TRIAL

CD34-SELECTEDALLOGENEIC HEMATOPOIETIC STEM CELLTRAN-SPLANTATION FOR PATIENTS WITH RELAPSED, HIGH-RISK MULTI-PLE MYELOMA

A PHASE 1, OPEN-LABEL, DOSE ESCALATION, SAFETY, PHARMA-COKINETICAND PHARMACODYNAMIC STUDYOFAFIRST IN CLASSPOL1 INHIBITOR (CX-5461) IN PATIENTS WITH ADVANCED HAEMA-TOLOGIC MALIGNANCIES (HM)

HIGHLY PROLONGED OVERALL SURVIVAL FOLLOWING REDUCEDINTENSITYALLOGENEIC STEMCELLTRANSPLANTATION FORMUL-TIPLE MYELOMA IN THE NEW DRUGS ERA

P. Richardson

C. Touzeau

C. Paba Prada

M. Mohty

A. Chari

A. Keller

M. Mohty

M. Offidani

A. López

G. Koehne

A. Khot

F. Rezzonico

PO-336

PO-337

PO-338

PO-339

PO-340

PO-341

PO-342

PO-343

PO-344

PO-346

PO-347

PO-348

ADVERSE EVENT (AE) MANAGEMENTWITH POMALIDOMIDE (POM)+ LOW-DOSEDEXAMETHASONE (LODEX) IN THESTRATUS™TRIAL:A PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY IN PA-TIENTS (PTS) WITH REFRACTORY OR RELAPSED AND REFRAC-TORY MULTIPLE MYELOMA (RRMM)

TREATMENT (TX) WITH POMALIDOMIDE (POM)AND LOW-DOSE DE-XAMETHASONE (LODEX) IN PATIENTS (PTS) WITH RELAPSED ORREFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IMPAIR-MENT (RI) INCLUDING THOSE ON DIALYSIS

A PHASE 1 STUDY OF THE PHARMACOKINETICS (PK) AND SAFETYOF POMALIDOMIDE + LOW-DOSEDEXAMETHASONE (POM+LODEX)IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLEMYELOMA (RRMM) AND RENAL IMPAIRMENT (RI)

OUTCOMESOFPATIENTS (PTS)WITHREFRACTORYORRELAPSEDAND REFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IM-PAIRMENT (RI) TREATEDWITH POMALIDOMIDE (POM) + LOW-DOSEDEXAMETHASONE (LODEX) IN THE PHASE 3B STRATUS™ TRIAL(MM-010)

EFFECT OF AGE ON OUTCOMES WITH POMALIDOMIDE (POM) +LOW-DOSEDEXAMETHASONE (LODEX) IN PATIENTS (PTS)WITHRE-FRACTORYORRELAPSEDANDREFRACTORYMULTIPLEMYELOMA(RRMM) IN THESTRATUSTMTRIAL (MM-010),ASINGLE-ARM, PHASE3B STUDY

ELOTUZUMAB: SERUM PROTEIN ELECTROPHORESIS AND IMMU-NOFIXATION INTERFERENCE WITH CLINICAL ASSESSMENT OF M-PROTEIN RESPONSE IN RELAPSED/REFRACTORY MULTIPLEMYELOMA (RRMM)

LONG TERM FOLLOW-UP OF A DONOR VERSUS NO DONOR COM-PARISON IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSEAFTER PREVIOUSAUTOTRANSPLANT

PHASE 1 CLINICAL TRIAL OF MARIZOMIB (MRZ, NPI-0052) IN PA-TIENTS WITH ADVANCED MALIGNANCIES INCLUDING MULTIPLEMYELOMA: STUDY NPI-0052-102 (NCT00629473) FINAL RESULTS

PHARMACOKINETICS OF DARATUMUMAB FOLLOWING INTRAVE-NOUS INFUSION IN RELAPSED OR REFRACTORY MULTIPLE MYE-LOMA (MM) AFTER PRIOR PROTEASOME INHIBITOR (PI) ANDIMMUNOMODULATORY DRUG (IMID) TREATMENT

BORTEZOMIB VERSUS LENALIDOMIDE IN MULTIPLE MYELOMA PA-TIENTS AT FIRST RELAPSE: FIRST INTERIM ANALYSIS OF A PHASEIII STUDY

IMPACTOFTREATMENTDURATIONANDDOSINGONEFFICACYANDSAFETY IN A PHASE 3 STUDY OF PANOBINOSTAT PLUS BORTEZO-MIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RE-LAPSEDAND REFRACTORYMULTIPLE MYELOMAPHASE 1/2 DOSE-ESCALATION STUDY OF MARIZOMIB (MRZ, NPI-

M. Cavo

P. Sonneveld

J. Matous

K. Weisel

A. Palumbo

M. Dimopoulos

F. Patriarca

S.J. Harrison

P.L. Clemens

V. Montefusco

J.F. San-Miguel

PO-325

PO-326

PO-327

PO-328

PO-329

PO-330

PO-331

PO-332

PO-333

PO-334

PO-335

POSTER SESSION

7170



OVERCOMINGPROTEASOME INHIBITORRESISTANCE INMULTIPLEMYELOMAUSING THE XPO1: INHIBITOR SELINEXOR

POSTRANSPLANT CYCLOPHOSPHAMIDE AS GVHD PROPHYLAXISIN PATIENTSWITHMULTIPLEMYELOMA. EXPECIENCEOFASINGLECENTER

INTRAVENOUSBORTEZOMIB (IV) INFUSIONAFTERNONRESPONSETO SUBCUTANEOUS BORTEZOMIB (SQ) ADMINISTRATION CAN IN-DUCETRANSITORYRESPONSES INMULTIPLEMYELOMAPATIENTS:IS SOME PATIENT MORE SENSITIVE TO THE IV BORTEZOMIB?

APHASE I STUDYOFTHEADDITIONOFHIGH-DOSE LENALIDOMIDETO MELPHALAN CONDITIONING FOR AUTOLOGOUS STEM-CELLTRANSPLANT IN RELAPSEDORREFRACTORYMULTIPLEMYELOMA

BENDAMUSTINE-BORTEZOMIB-DESAMETASONE (BVD) IN THE MA-NAGEMENTOFRELAPSEDANDREFRACTORYMULTIPLEMYELOMA:AREGIONAL REAL-LIFE EXPERIENCE

POMALIDOMIDE-CONTAININGREGIMENS FORTHETREATMENTOFRELAPSEDAND REFRACTORYMULTIPLE MYELOMA

EFFICACYAND SAFETY OF LENALIDOMIDE (LEN) PLUS LOW-DOSEDEXAMETHASONE (DEX; RD) IN CHINESE PATIENTS (PTS)WITHRE-LAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) ACCORDINGTO DISEASE STAGE (INTERNATIONAL STAGING SYSTEM [ISS]): RE-SULTS FROM THE MM-021 TRIAL AND MM-024 EXTENDED ACCESSPROGRAM (EAP)

TWO RANDOMIZED OPEN-LABEL STUDIES OF DARATUMUMAB(DARA) PLUS STANDARD OF CARE TREATMENT VERSUS STAN-DARD OF CARE ALONE IN PATIENTS WITH PREVIOUSLY UNTREA-TED MULTIPLE MYELOMA (MM) INELIGIBLE FOR HIGH-DOSETHERAPY: 54767414MMY3007 (ALCYONE) AND 54767414MMY3008(MAIA)

MYELOABLATIVE TIMED SEQUENTIAL BUSULFAN IS SAFE IN PA-TIENTS WITH RELAPSED OR HIGH-RISK MULTIPLE MYELOMA

PEGYLATED LIPOSOMAL DOXORUBICINE, CYCLOPHOSPHAMIDEAND DEXAMETASONE (CED): A NEW OPPORTUNITY IN RELAPSEDAND REFRACTORYMULTIPLE MYELOMA

LENALIDOMIDE EXPAND CD3+CD56+ T CELL CYTOKINE INDUCEDKILLER (CIK) CELLS IN VIVO IN MULTIPLE MYELOMAPATIENTS

ORALCYCLOPHOSPHAMIDE INRELAPSED/REFRACTORYMULTIPLEMYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURINGLENALIDOMIDE-DEXAMETHASONETREATMENT: RESULTSOFARE-TROSPECTIVE MULTICENTERANALYSIS

MULTIPLE INFUSIONS OF AUTOLOGOUS ACTIVATED AND EXPAN-DED NATURAL KILLER CELLS: A NEW THERAPEUTIC OPTION FORMULTIPLE MYELOMA

D.M. Sullivan

L. Rosiñol

A. Gozzetti

P. Forsberg

C. Cerchione

V.H. JimenezZepeda

J. Hou

T. Facon

M.H. Qazilbash

C. Cerchione

H. Handa

L. Cesini

A. Leivas

PO-362

PO-363

PO-364

PO-365

PO-366

PO-367

PO-368

PO-369

PO-370

PO-371

PO-372

PO-373

PO-374

DURABLE REMISSION AND SURVIVAL IN RELAPSED/REFRACTORYMULTIPLE MYELOMA AFTER ALLOGENEIC HEMATOPOIETIC STEMCELL TRANSPLANTATION

AUTOPHAGY AND MTOR INHIBITION AS MECHANISMS FOR COM-BATTING CHEMORESISTANCE TO STANDARD CHEMOTHERAPY:FINAL RESULTS OF A PHASE I STUDY OF INFUSIONAL CYCLOPHO-SPHAMIDE (CY), PULSE DEXAMETHASONE (DEX), RAPAMYCIN(RAPA) AND HYDROXYCHLOROQUINE (HCQ)

WILMS’ TUMOR 1 PROTEIN IS HIGHLY EXPRESSED ON MALIGNANTPLASMA CELLS AND PROVIDES A NOVEL TARGET FOR IMMUNO-THERAPEUTICAPPROACHES

EFFICACY AND SAFETY OF PRE-APPROVAL CARFILZOMIB-BASEDTHERAPY OF MULTIPLE MYELOMA IN DAILY PRACTICE – EXPE-RIENCE FROMAGERMANACADEMIC CENTER

LOWER DOSE LENALIDOMIDE-DEXAMETHASONE IS LESS TOXICAND DOES NOT COMPROMISE EFFICACY FOR PATIENTS WITH RE-LAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE AGED ≥60YEARS AND/OR WITH RENAL IMPAIRMENT AND/OR WITH THROM-BOCYTOPENIA

SAR650984 (SAR) DIRECTLY INDUCES MULTIPLE MYELOMA (MM)CELL DEATH VIA LYSOSOMAL-ASSOCIATED AND APOPTOTIC PA-THWAYS, WHICH IS FURTHER ENHANCED BY POMALIDOMIDE

VACCINE BASED IMMUNOTHERAPY AS A STRATEGY TO BYPASSDRUG RESISTANCE IN MULTIPLE MYELOMA

IDENTIFICATION OF PRECISION TREATMENT STRATEGIES FOR HIGHRISKMULTIPLEMYELOMABYEXVIVODRUGSENSITIVITYTESTING

APHASE 1/2 TRIALOFTHE INSULINGROWTHFACTOR 1RECEPTOR(IGF-1R) INHIBITOR, LINSITINIB IN COMBINATION WITH BORTEZO-MIB (BTZ) AND DEXAMETHASONE (DEX) FOR THE TREATMENT OFRELAPSED/REFRACTORYMULTIPLE MYELOMA (MM)

THE CONTRIBUTION OF A THIRD AUTOLOGOUS STEM CELL TRAN-SPLANT IN THE ERA OF NOVEL AGENTS: FAVOURABLE OVERALLSURVIVALAND IMPROVEMENT OF EXHAUSTED BONE MARROWFUNCTION

OUTCOME OF POMALIDOMIDE THERAPY IN RELAPSED / REFRAC-TORY MYELOMA: AUK MULTI-CENTRE EXPERIENCE

RENAL RESPONSE IN PATIENTS (PTS) WITH RELAPSED REFRAC-TORY MULTIPLE MYELOMA (RRMM) AND SEVERE RENAL IMPAIR-MENT (RI): INTERIM DATA FROM A LARGE OBSERVATIONAL,PROSPECTIVE STUDY

LENALIDOMIDE LONG-TERM NEUROTOXICITY: NEUROPHYSIOLO-GICAL FOLLOW-UP STUDY IN PATIENTS WITH RELAPSED/REFRAC-TORY MYELOMA

A.M. Cornelison

E.C. Scott

G. Koehne

S. Danhof

H. Quach

H. Jiang

C. Wang

M.M. Majumder

S. Trudel

S. Strifler

N. Maciocia

A. García-Guiñon

A. Liço

PO-349

PO-350

PO-351

PO-352

PO-353

PO-354

PO-355

PO-356

PO-357

PO-358

PO-359

PO-360

PO-361

7372



CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA,SINGLE CENTER EXPERIENCE

ECONOMIC ANALYSIS OF LENALIDOMIDE/DEXAMETHASONE(LEN/DEX) VS. BORTEZOMIB (BORT) FOR THE TREATMENT OF RE-LAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN CHINA

BORTEZOMIB PRETREATMENTBEFOREALLOGENIC HEMATOPOIE-TIC STEMCELLTRANSPLANTATIONFORRELAPSEDMULTIPLEMYE-LOMA

MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE (MGRS).RAPID HEMATOLOGICAL AND RENAL COMPLETE RESPONSE TOBORTEZOMIB

SAFETY OF LENALIDOMIDE (LEN) PLUS LOW-DOSE DEXAMETHA-SONE (DEX; RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED/RE-FRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH PRIORTHALIDOMIDE (THAL) AND BORTEZOMIB (BORT): SUBANALYSIS OFTHE MM-024 EXTENDEDACCESS PROGRAM (EAP)

THE EFFICACYAND SAFETY OF LENALIDOMIDE IN MULTIPLE MYE-LOMAWITH SEVERE RENAL IMPAIRMENT

ANATIONALEXPERIENCEOFTHEEFFICACYANDSAFETYOF LONG-TERM TREATMENT WITH LENALIDOMIDE IN PATIENTS WITH RE-LAPSED MULTIPLE MYELOMA

IS URINE IMMUNOFIXATIONELECTROPHORESIS NECESSARY FORMONITORING MYELOMAPATIENTSWHO HAS UNDERGONE HEMA-TOPOIETIC STEM CELL TRANSPLANTATION

POMALIDOMIDE IN REFRACTORY MULTIPLE MYELOMA (MMRR): ASINGLE CENTER EXPERIENCE

METRONOMIC CHEMOTHERAPY OF THALIDOMIDE, CYCLOPHO-SPHAMIDE, AND DEXAMETHASONE FOR RELAPSED/REFRACTORYMULTIPLE MYELOMAPATIENTS

SYNCHRONOUS LOCALIZATIONS OF MULTIPLE MYELOMA IN 3 DIF-FERENT SITES (ETHMOIDAL SINUSES, TESTICLES AND SKIN) DU-RING THE COURSE OF MULTIPLE MYELOMA (MM) THERAPY

IGDMULTIPLEMYELOMA, DESCRIPTIVE REPORTOFEIGHTCASES,SINGLE CENTRE EXPERIENCE

CASE REPORT: POMALIDOMIDE AS CONSOLIDATION THERAPYAFTER SALVAGEAUTOLOGOUS STEM CELL TRANSPLANT

Y. Aydin

Z. Shen

S.N. Lim

A. Alegre

L. Yu

K.S. Jung

M.I. Pereira

R. Haznedar

C. MontesGaisan

H.J. Kim

G. Mele

S. Ongoren

M. Steinbach

PO-388

PO-389

PO-390

PO-391

PO-392

PO-393

PO-394

PO-395

PO-396

PO-397

PO-398

PO-399

PO-400

A SINGLE CENTRE RETROSPECTIVE ANALYSIS OF THE ADDITIONOF CLARITHROMYCIN (BIAXIN) TO LENALIDOMIDE AND DEXAME-THASONE (LEN-DEX) DURING TIME OF PROGRESSIVE DISEASE INPATIENTS WITH MULTIPLE MYELOMA (MM)

ANON-INTERVENTIONALOBSERVATIONALREGISTRYOFPATIENTS(PTS)WITHRELAPSED/REFRACTORYMULTIPLEMYELOMA(RRMM)TREATEDWITH LENALIDOMIDE (LEN)ANDDEXAMETHASONE (DEX)IN TAIWAN

A NON-INTERVENTIONAL, OBSERVATIONAL REGISTRY OF ADULTPATIENTSWITHMULTIPLEMYELOMATREATEDWITHREVLIMID (LE-NALIDOMIDE) IN CHINA: INTERIMANALYSIS

PACE AS SALVAGE THERAPY FOR RELAPSED OR REFRACTORYMULTIPLE MYELOMA

COMBINATION CARFILZOMIB AND THE VIRAL ONCOLYTIC AGENTREOLYSIN IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: APILOT STUDY INVESTIGATING VIRAL PROLIFERATION

POST-AUTHORIZATION SAFETY OF LENALIDOMIDE + DEXAMETHA-SONE IN PATIENTSWITHRELAPSED/REFRACTORYMULTIPLEMYE-LOMA IN TURKEY

EFFICACY OF POMALIDOMIDE AFTER PROGRESSION FOLLOWINGLENALIDOMIDE AND BORTEZOMIB-A MULTICENTER RETROSPEC-TIVE STUDY

LENALIDOMIDE FOR HEAVILY PRETREATED RELAPSED/REFRAC-TORYMYELOMACOHORT IN NORTHWESTUNITEDKINGDOM (UK) –EFFICACY & TOLERABILITY: HIGH RESPONSE & LOW SECOND MA-LIGNANCY RATES

EFFECTIVENESSOF LENALIDOMIDETREATMENT IN PATIENTSWITHVERYSEVERERENAL IMPAIRMENTANDRELAPSEDMULTIPLEMYE-LOMA

EFFICACYAND TOXICITYOF THE COMBINATION THERAPYOF THA-LIDOMIDE, ALKYLATING AGENT, AND CORTICOSTEROID FOR RE-LAPSED/REFRACTORYMYELOMAPATIENTS :AREPORTFROMTHEKOREAN MULTIPLE MYELOMAWORKING PARTY (KMMWP) RETRO-SPECTIVE STUDY

IMPACT OF IMMUNOGLOBULIN (IG) D SUBTYPE ON THE EFFICACYAND SAFETY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHA-SONE (RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED/REFRAC-TORY MULTIPLE MYELOMA (RRMM): MM-021 TRIAL

POMALIDOMIDE BASED THERAPY IN PATIENTS WITH SEVERERENAL IMPAIRMENT

INCIDENCE OF THROMBOSIS IN MULTIPLE MYELOMA PATIENTSTREATEDWITH LENALIDOMIDE-DEXAMETHASONE INOURCENTER.THE INFLUENCE OF RISK FACTORS

R. Kaedbey

S.Y. Huang

J. Lu

I. Isola

D.W. Sborov

A.T. FıratlıTuğlular

O. Miles

J.A. Chadwick

C. João

J. Kwon

Z. Cai

J. Richter

M. Garcia-Fortes

PO-375

PO-376

PO-377

PO-378

PO-379

PO-380

PO-381

PO-382

PO-383

PO-384

PO-385

PO-386

PO-387

7574



Nizar J. Bahlis Calgary, CanadaSara Bringhen Torino, ItalyRaymond L. Comenzo Boston, USAMeletios A. Dimopoulos Athens, GreeceAngela Dispenzieri Rochester, USABeth Fainan Cleveland, USAFrancesca Gay Torino, ItalyIrene M. Ghobrial Boston, USAAndrzej Jakubowiak Chicago, USATracy King Sidney, AustraliaShaji K. Kumar Rochester, USASagar Lonial Atlanta, USAValeria Magarotto Torino, ItalyMaria-Victoria Mateos Salamanca, SpainGiampalolo Merlini Pavia, ItalyFortunato Morabito Cosenza, ItalyGareth J. Morgan Little Rock, USAPellegrino Musto Rionero in Vulture (PZ), ItalyMassimo Offidani Ancona, ItalyStefania Oliva Torino, ItalyTorben Plesner Vejle, DenmarkNoopur Raje Boston, USAS. Vincent Rajkumar Rochester, USAAndrew Spencer Melbourne, AustraliaA. Keith Stewart Scottsdale, USAElena Zamagni Bologna, ItalySonja Zweegman Amsterdam, The Netherlands

7. Nurse Session

POSTER SESSION

MANAGEMENT OF TOXICITIES ASSOCIATED WITH CARFILZOMIB:AN UPDATE OF THE ITALIAN EXPERIENCE

DEVELOPING SAFE HAEMATOLOGICAL MONITORING GUIDELINESFOR PATIENTS WITH MYELOMA ON BORTEZOMIB BASEDREGIMENS

HOW A PATIENT SATISFACTION SURVEY CAN ENHANCE AMYELOMAOUT PATIENT CLINIC

ARE THE MYELOMA POPULATION COMPUTER LITERATE? –SQUASHING THE SNAIL MAIL

DEVELOPING A NURSE LED, HOLISTIC NEEDS ASSESSMENTCLINIC FOR MYELOMA PATIENTS

A. Bernardini

C. Woodrow

C. Marrin

H. King

J. Helwlett

PO-401

PO-402

PO-403

PO-404

PO-405

ABSTRACT REVIEWERS

programma ses - er congressi final program.pdf · 15 th international myeloma workshop w w w. i m w...

Documents